SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS Technical field The present invention relates to novel spiro[cyclobutane-1,3'-indolin]-2'-one derivatives of formula (I) which are useful as bromodomain inhibitors and to pharmaceutical compositions thereof. The invention relates also to the use of compounds of formula (I) for the treatment or prevention of diseases or disorders, in particular those where bromodomain inhibition is desired. Background of the invention The acetylation of histone lysine is central for providing the dynamic regulation of chromatin-based gene transcription. The bromodomain (BRD), which is the conserved structural module in chromatin-associated proteins and histone acetyl- tranferases, is the sole protein domain known to recognize acetyl-lysine residues on proteins. The BET family of bromodomain containing proteins comprises 4 proteins (BRD2, BRD3, BRD4 and BRD-t) which contain tandem bromodomains capable of binding to two acetylated lysine residues in close proximity, increasing the specificity of the interaction. BRD2 and BRD3 are reported to associate with histones along actively transcribed genes and may be involved in facilitating transcriptional elongation (Leroy et al, Mol. Cell., 2008, 30(1):51 -60), while BRD4 appears to be involved in the recruitment of the pTEF-[beta] complex to inducible genes, resulting in phosphorylation of RNA polymerase and increased transcriptional output (Hargreaves et al., Cell, 2009, 138(1): 129-145). It has also been reported that BRD4 or BRD3 may fuse with NUT (nuclear protein in testis) forming novel fusion oncogenes, BRD4-NUT or BRD3-NUT, in a highly malignant form of epithelial neoplasia (French et al., Cancer Research, 2003, 63, 304-307 and French et al., Journal of Clinical Oncology, 2004, 22 (20), 4135-4139). Data suggests that BRD- NUT fusion proteins contribute to carcinogenesis (Oncogene, 2008, 27, 2237-2242). BRD-t is uniquely expressed in the testes and ovary. All family members have been reported to have some function in controlling or executing aspects of the cell cycle, and have been shown to remain in complex with chromosomes during cell division suggesting a role in the maintenance of epigenetic memory. In addition some viruses make use of these proteins to tether their genomes to the host cell chromatin, as part of the process of viral replication (You et al., Cell, 2004 1 17(3):349-60). Japanese patent application JP 2008-156311 discloses a benzimidazole derivative which is said to be a BRD2 bromodomain binding agent which has utility with respect to virus infection / proliferation. International patent application WO 2009/084693 discloses a series of thienotriazolodiazepiene derivatives that are said to inhibit the binding between an acetylated histone and a bromodomain containing protein and are said to be useful as anti-cancer agents. International patent application WO 2011/054846 discloses a series of quinoline derivatives that inhibit the binding of BET family bromodomains with acetylated lysine residues. However, there remains a need for potent bromodomain inhibitors with desirable pharmaceutical properties. Certain spiro[cyclobutane-1,3'-indolin]-2'-one derivatives have been found according to the present invention which inhibit the binding of BET family bromodomains to acetylated lysine residues. Such compounds will hereafter be referred to as "bromodomain inhibitors". Summary of the invention The present invention provides new spiro[cyclobutane-1,3'-indolin]-2'-one derivatives which are able to inhibit the binding of BET family bromodomains to acetylated lysine residues. The present invention provides a compound of formula (I): wherein Cy is a 4-12 membered monocyclic or bicyclic ring containing 0-4 hetero- atoms independently selected form N, O or S; L is a linker selected from -N(R3a)S(O)2-, -S(O)2N(R3b)-, -C(R3c)(OR3d)-, -N(R3e)C(O)-, -N(R3f)C(O)N(R3g)- or -N(R3h)C(O)CH(R3i)-; R3a, R3b,R3c,R3d,R3e, R3f, R3g, R3h, and R3i are selected, independently, from hydrogen or C1-7alkyl; R2 is halogen, C1-7 alkoxy, amino, cyano, oxo, -C(O)O-C1-7 alkyl, optionally substituted aryl or optionally substituted heterocyclyl, wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen or C1-7 alkoxy; in case wherein L is -S(O)2N(R3b)-, -C(R3c)(OR3d)-, -N(R3e)C(O)-, -N(R3f)C(O)N(R3g)- or -N(R3h)C(O)CH(R3i)-; then R1 is hydrogen, C1-7 alkyl, halogen, hydroxy C1-7 alkyl, C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl C1-7 alkyl, optionally substituted aryl C2-7 alkenyl, -NRaRb; -C(O)NRcRd, -C(O)ORe, -C(O)Rf, -C(ORs)-aryl, -C(ORh)(Ri)-aryl or -ORj; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, C1-7 alkyl or C1-7 alkoxy; except that R1 is not hydrogen when L is -S(O)2NH- or -CH(OH)-, and R1 is not hydrogen or halogen when L is -NHC(O)CH(CH3)-; in case wherein L is -N(R3a)S(O)2- then R1 is -NRaRb, -C(O)NRcRd, -C(O)ORe, -C(O)Rf,-C(ORg)-aryl, -C(ORh)(Ri)-aryl or -ORj, -CH(CH3)-aryl, hydroxy C1-7 alkyl, aryl halo C1-7 alkyl, optionally substituted heterocyclyl C1-7alkyl3 optionally substituted aryl, optionally substituted aryl C2-7alkenyl, optionally substituted 9-12 membered heterocyclic ring having 1-3 heteroatoms selected from N or O, pyridinyl having 1-2 substituents selected from halogen, hydroxy or C1-7alkoxy, 2-oxopiperidinyl, fluorophenyl C1-7 alkyl, 1-methylpiperidinyl (when at least one of R2 is halogen), piperidinyl (when at least two of R2 is C1-7alkoxy), phenyl C1-7alkyl (when at least one of R2 is halogen and at least one another of R2 is C1-7alkoxy); wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, oxo, C1-7 alkyl or C1-7 alkoxy; Ra, Rb, Re and Rd are, independently, selected from hydrogen, C1-7 alkyl, C2-7 alkenyl, -C(O)-C 1-7 alkyl, optionally substituted heterocyclyl, optionally substituted C3-10cycloalkyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl, optionally substituted aryl C1-7 alkyl, optionally substituted C3-10 cycloalkyl C1-7 alkyl, optionally substituted -C(O)heterocyclyl; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl, -C(O)-C 1-7 alkyl, -C(O)O-C1-7 alkyl, halogen, aryl C1-7 alkyl, C 1-7 alkoxy, oxo or. hydroxy C 1-7 alkyl; Re, Rf, Rg, Rh, Ri and Rj are, independently, selected from hydrogen, C1-7 alkyl, optionally substituted aryl or optionally substituted heterocyclyl wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl or hydroxy C1-7 alkyl; and 'm' is selected from 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof. 1 In a further aspect, the present invention provides a pharmaceutical composition comprising spiro[cyclobutane-1,3'-indolin]-2'-one derivative of formula (I) or a pharmaceutically acceptable salt thereof. In yet further aspect of the present invention, it provides spiro[cyclo- butane-1,3'-ihdolin]-2'-one derivatives of formula (I) or a pharmaceutically acceptable thereof for use in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired, in particular for the treatment or prevention of an autoimmune disease, inflammatory disease or cancer. Detailed description of the invention An embodiment of the present application provides novel spiro[cyclobutane- 1,3'-indolin]-2'-one derivatives of formula (I) or pharmaceutically acceptable salts thereof which are useful as bromodomain inhibitors. One of the embodiments of the present invention provides a compound of formula (I): wherein Cy is a 4-12 membered monocyclic or bicyclic ring containing 0-4 hetero- atoms independently selected form N, O or S; L is a linker selected from -N(R3a)S(O)r, -S(O)2N(R3b)-, -C(R3c)(OR3d)-, -N(R3e)C(O)-, -N(R3f)C(O)N(R3g)- or -N(R3h)C(O)CH(R3i)-; R3a, R3b,R3c,R3d.R3<;, R3f, R3g, R3h and R3i are selected, independently, from hydrogen or C1-7 alkyl; R2 is halogen, C1-7alkoxy, amino, cyano, oxo, -C(O)O-C1-7 alkyl, optionally substituted aryl or optionally substituted heterocyclyl, wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen or C1-7 alkoxy; in case wherein L is -S(O)2N(R3b)-, -C(R3c)(OR3d)-, -N(R3e)C(O)-, -N(R3f)C(O)N(R3g)- or -N(R3h)C(O)CH(R3,)-; then Ri is hydrogen, C1-7alkyl, halogen, hydroxy C1-7alkyl, C3-10cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl C1-7alkyl, optionally substituted aryl C1-7 alkyl, optionally substituted aryl C2-7alkenyl, -NRaRb) -C(O)NRcRd, -C(O)ORe, -C(O)Rf,-C(ORg)-aryl, -C(ORh)(Ri)-aryl or -OR,; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, C1-7 alkyl or C1-7 alkoxy; except that R1 is not hydrogen when L is -S(O)2NH- or -CH(OH)-, and R1 is not hydrogen or halogen when L is -NHC(O)CH(CH3)-; in case wherein L is -N(R3a)S(O)2- then R1 is -NRaRb, -C(O)NRcRd, -C(O)OR, -C(O)Rf,-C(ORg)-aryl, -C(ORh)(Ri)-aryl or -ORj, -CH(CH3)-aryl, hydroxy C1-7 alkyl, aryl halo d.7 alkyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl, optionally substituted aryl C2.7alkenyl, optionally substituted 9-12 membered heterocyclic ring having 1-3 heteroatoms selected from N or O, pyridinyl having 1-2 substituents selected from halogen, hydroxy or C1-7 alkoxy, 2-oxopiperidinyl, fluorophenyl C1-7 alkyl, 1-methylpiperidinyl (when at least one of R2 is halogen), piperidinyl (when at least two of R2 is C1-7 alkoxy), phenyl C1-7 alkyl (when at least one of R2 is halogen and at least one another of R2 is C1-7 alkoxy); wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, oxo, C1-7 alkyl or C1-7 alkoxy; Ra, Rb, Re and Rd are, independently, selected from hydrogen, C1-7 alkyl, C2.7 alkenyl, -C(O)-C1-7 alkyl, optionally substituted heterocyclyl, optionally substituted C3-10cycloalkyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl, optionally substituted aryl C1-7 alkyl, optionally substituted C3-10cycloalkyl C1-7 alkyl, optionally substituted -C(O)heterocyclyl; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl, -C(O)-C 1.7 alkyl, -C(O)O-C1-7 alkyl, halogen, aryl C1-7 alkyl, C1-7 alkoxy, oxo or hydroxy C1-7 alkyl; Re, Rf, Rg, Rh, R; and Rj are, independently, selected from hydrogen, C1-7 alkyl, optionally substituted aryl or optionally substituted heterocyclyl wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl or hydroxy C1-7 alkyl; and 1 'm' is selected from 0, 1,2 or 3; or a pharmaceutically acceptable salt thereof. It is to be understood that the left bond in each linker L is attached to the indolinone ring of formula (I). The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified. • According to one embodiment of the present invention, the compound of formula (I) is a compound of formula (IA) wherein R1, R2, Cy, L and 'm' are same as defined in formula (I), or a pharmaceutically acceptable, salt thereof. According to yet another embodiment of the present invention, the compound of formula (I) is a compound of formula (IB) wherein R1, R2,R3a, Cy and 'm' are same as defined in formula (I), or a pharmaceutically acceptable salt thereof. According to yet another embodiment of the present invention, the compound of formula (I) is a compound of formula (IC) wherein R1, R2, R3f, R.3g, Cy and 'm' are same as defined in formula (I), or a pharmaceutically acceptable salt thereof. According to yet another embodiment of the present invention, the compound of formula (I) is a compound of formula (ID) wherein R1, R2,R3e, Cy and 'm' are same as defined in formula (I), or a pharmaceutically acceptable salt thereof. According to one embodiment, specifically provided are compounds of formula (I ) wherein Cy is phenyl, C3-10 cycloalkyl or a 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from N or O; L is a linker selected from -N(R3a)S(O)2-, -N(R3e)C(O)- or -N(R3f)C(O)N(R3g)-; R3a, R3=, R3f and R3g, are selected, independently, from hydrogen or C1-7alkyl; R2 is halogen, C1-7alkoxy, cyano, -C(O)O-C1-7alkyl or a 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from N or O; in case wherein L is -N(R3e)C(O)- or -N(R3f)C(O)N(R3g)- then R1 is hydrogen, C1-7alkyl, halogen, hydroxy C1-7alkyl, C3-10cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl C1-7 alkyl, optionally substituted aryl C1-7 alkenyl, -NRaRb, -C(O)NRcRd, -C(O)ORe, -C(O)Rf,-C(ORg)-aryI, -C(ORh)(R)-aryl or -ORJ; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, C1-7 alkyl or C1-7 alkoxy; in case wherein L is -N(R3a)S(O)2- then R1 is -NRaRb, -C(O)NRcRd, -C(O)ORe, -C(O)Rf,-C(ORg)-aryl, -C(ORh)(Ri)-aryl or -ORj, -CH(CH3)-aryl, hydroxy C1-7 alkyl, aryl halo C1-7 alkyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl, optionally substituted aryl C2-7 alkenyl, optionally substituted 9-12 membered heterocyclic ring having 1-3 heteroatoms selected from N or O, pyridinyl having 1-2 substituents selected from halogen, hydroxy or C1-7 alkoxy, 2-oxopiperidinyl, fluorophenyl C1-7 alkyl, 1-methylpiperidinyl (when at least one of R2 is halogen), piperidinyl (when at least two of R2 is C1-7 alkoxy), phenyl C1-7 alkyl (when at least one of R2 is halogen and at least one another of R2 is C1-7 alkoxy); wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, oxo, C 1-7 alkyl or C1-7 alkoxy; Ra, Rb, Re and Ri are, independently, selected from hydrogen, C1-7 alkyl, C2.7 alkenyl, -C(O)-C1-7 alkyl, optionally substituted heterocyclyl, optionally substituted G-10 cycloalkyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl, optionally substituted aryl C1-7 alkyl, optionally substituted G-10 cycloalkyl C1-7 alkyl, optionally substituted-C(O)heterocyclyl; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl, -C(O)-C1-7 alkyl, -C(O)0-C1-7 alkyl, halogen, aryl C1-7 alkyl, C1-7 alkoxy, oxo or hydroxy C 1.7 alkyl; Re, Rf, Rg, Rh, R and Rj are, independently, selected from hydrogen, C1-7 alkyl, optionally substituted aryl or optionally substituted heterocyclyl wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl or hydroxy C1-7 alkyl; and 'm' is selected from 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof. • According to one embodiment, specifically provided are compounds of formula (I), (IA), (IB), (IC) or (ID), wherein Cy is aromatic or non-aromatic cyclic ring with 5-10 ring atoms of which 0-4 are heteroatoms selected from a group consisting of N, 0 and S. In a subclass of the above embodiment are compounds wherein Cy is phenyl, C3-10 cycloalkyl or a 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from N or O. In yet another subclass of the above embodiment are compounds wherein Cy is phenyl, cyclohexyl or piperidinyl. According to one embodiment, specifically provided are compounds of formula (I), (IA), (IB), (IC) or (ID), or according to any other embodiment, or subclass referred to above, wherein L is a linker selected from -NHS(O)2-, -NHC(O)- or -NHC(O)NH-. In a subclass of the above embodiment are compounds wherein L is -NHS(O)2-. According to yet one embodiment, specifically provided are compounds of formula (I), (IA) or (IB), wherein Cy is phenyl; L is -NHS(O)2-; R2 is halogen or C1-7 alkoxy, R1 is -NHRa, -C(O)NHRc, -C(O)OR^, -C(O)Rf,- C(OH)phenyl, -C(OH)( C1-7alkyl)phenyl or -ORj, -CH(CH3)phenyl, hydroxy d.7 alkyl, aryl halo C1-7alkyl, optionally substituted heterocyclyl C1-7alkyl, optionally substituted phenyl, optionally substituted phenyl C2.7 alkenyl, optionally substituted 9-12 membered heterocyclic ring having. 1-3 heteroatoms selected from N or O, pyridinyl having 1-2 substituents selected from halogen, hydroxy or C1-7alkoxy, 2- oxopiperidinyl, fluorophenyl C1-7alkyl, 1-methylpiperidinyl (when at least one of R2 is halogen), piperidinyl (when at least two of R2 is C1-7alkoxy), phenyl C1-7 alkyl (when at least one of R2 is halogen and at least one another of R2 is C1-7alkoxy); wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, oxo, C1-7alkyl or C|.7alkoxy; 1 Ra and Re are, independently, selected from hydrogen, C1-7 alkyl, C2.7 alkenyl, -C(O)-C|.7 alkyl, optionally substituted C3.|0 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted C3.10 cycloalkyl C1-7 alkyl, optionally substituted-C(O)heterocycly 1; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C,.7allcyl, -C(O)-C1-7alkyl, -C(O)0-C1-7 alkyl, halogen, phenyl C1-7 alkyl, C1-7alkoxy, oxo or hydroxy C1-7 alkyl; Re is hydrogen or C1-7 alkyl; i Rf and Rj are independently optionally substituted phenyl or optionally substituted heterocyclyl wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl or hydroxy C1-7 alkyl; wherein heterocyclyl at each occurrence is a 5-10 membered heterocyclic ring having 1-4 heteroatoms selected from O, N, or S; and 'm' is selected from 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof. In one subclass of any of the above embodiments are compounds of formula (I), (IA), (IB), (IC) or (ID), wherein Cy-(R2)m is selected from one of the following groups or tautomers thereof According to one embodiment, specifically provided are compounds of formula (I), (IA), (IB), (IC) or (ID) wherein R, is -NRaRb) -C(O)NRcRd, -C(O)ORe, -C(O)Rf,-C(ORg)-aryl, -C(ORh)(Ri)-aryl or -ORj, -CH(CH3)-aryl, hydroxy C1-7 alkyl, aryl halo C1-7alkyl, optionally substituted heterocyclyl C1-7alkyl, optionally substituted aryl, optionally substituted aryl C2-7alkenyl, optionally substituted 9-12 membered heterocyclic ring having 1-3 heteroatoms selected from N or O, pyridinyl having 1-2 substituents selected from halogen, hydroxy or C1-7alkoxy, 2-oxo- piperidinyl, fluorophenyl C1-7 alky 1, 1-methylpiperidinyl (when at least one of R2 is halogen), piperidinyl (when at least two of R2 is C1-7alkoxy), phenyl C1-7 alkyl (when at least one of R2 is halogen and at least one another of R2 is C1-7alkoxy); wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, oxo, C1-7alkyl or C1-7alkoxy. In one subclass of the above embodiment are compounds wherein Ri is -NRaRb or -C(O)NRcRd, and Ra, Rb, Rc and Rj are, independently, selected from hydrogen, optionally substituted heterocyclyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted C3.10 cycloalkyl C1-7 alkyl, wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C,.7 alkyl, -C(O)-C,.7 alkyl, -C(O)0-C1-7 alkyl, halogen, aryl C1-7alkyl, C1-7alkoxy, oxo or hydroxy C 1.7 alkyl. According to one embodiment are compounds of formula (I), (IA), (IB), (IC) or (ID), or according to any embodiment or subclass referred to above, wherein Ri is optionally substituted heterocyclyl or optionally substituted heterocyclyl C1-7 alkyl; in particular selected from one of the following groups or tautomers thereof According to one embodiment, provided are compounds according to any embodiment or subclass referred to above, wherein R1 is -NRaRb or -C(O)NRcRd; in particular Ra, Rb, Re and Rd being independently selected from hydrogen, C1-7 alkyl (such as methyl), C2-7 alkenyl (such as but-1-ene), -C(O)-C1-7 alkyl (such as -C(O)CH3), or from one of the following groups or tautomers thereof According to one embodiment, specifically provided are compounds according to any embodiment or subclass referred to above, wherein heterocyclyl at each occurrence is a 5-10 membered heterocyclic ring having 1-4 heteroatoms selected from O, N, or S. In yet another particular embodiment of the present invention, the compound of formula (I) is selected from the group consisting of: or pharmaceutically acceptable salts thereof. In yet another embodiment according to the present patent application, it provides a pharmaceutical composition comprising a compound of formula (I), (TA), (IB) (IC) or (ID) of the present invention and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent). Preferably, the pharmaceutical composition comprises a therapeutically effective amount of at least one compound described herein. It should be understood that formulas (I), (IA), (IB) (IC) and (ID) encompass all stereoisomers, enantiomers and diastereomers that may be contemplated from the chemical structure of the compounds according to above formulas. The present compounds may also exist as tautomers or equilibrium mixtures thereof wherein a proton of a compound shifts from one atom to another. Examples of tautomers include, but are not limited to, amido-imido, keto-enol, phenol-keto, oxime-nitroso, nitro-aci, imine-enamine and the like. All tautomeric forms of the compounds are intended to be encompassed by their structural formula even though only one tautomeric form may be depicted. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in art to which the subject matter herein belongs. As used herein, the following definitions are supplied in order to facilitate the understanding of the present invention. The term "C1-7alkyl", as employed herein as such or as part of another group, refers to a straight or branched chain saturated hydrocarbon group having 1, 2, 3, 4, 5, 6 or 7 carbon atom(s). Representative examples of C1-7alkyl include, but are not limited to, methyl, ethyl, rc-propyl, wo-propyl, rc-butyl, wo-butyl, sec-butyl, ter/-butyl, n-pentyl, wo-pentyl and n-hexyl. The term "C 1-3 alky 1" refers to an preferred embodiment of "C1-7alkyl" having 1, 2 or 3 carbon atoms. The term "C2-7 alkenyl", as employed herein as such or as part of another group, refers to an aliphatic hydrocarbon group having 2 to 7 carbon atoms and containing one or several double bonds. Representative examples include, but are not limited to, ethylene, prop-J-ene, but-1-ene, but-2-ene, pent-1-ene, pent-2-ene, hex-1- ene and hex-2-ene. The term "C3-10 cycloalkyl", as employed herein as such or as part of another group, refers to a saturated or partially saturated, monocyclic, bicyclic or polycyclic hydrocarbon ring system having 3 to 10 carbon atoms. Examples of C3-10 cycloalkyl groups are include those where saturated 5 or 6 membered cycloalkyl ring is fused to a phenyl ring. The term "C3-7 cycloalkyl", as employed herein as such or as part of another group, refers to a saturated or partially saturated monocyclic hydrocarbon ring containing 3, 4, 5, 6 or 7 carbon atoms. Representative examples of C3-10 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "halo" or "halogen", as employed herein as such or as part of another group, refers to chlorine, bromine, fluorine or iodine. The term "C1-7 alkoxy", as employed herein as such or as part of another group, refers to C1-7alkyl, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of C1-7 alkoxy include, but are not limited to methoxy, ethoxy, propoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy. The term "hydroxy", as employed herein as such or as part of another group, refers to an —OH group. The term "amino", as employed herein as such or as part of another group, refers to an -NH2 group. The term "cyano", as employed herein as such or as part of another group, refers to a -CN group. The term "carboxy", as employed herein as such or as part of another group, refers to -COOH group. The term "carbonyl", as employed herein as such or as part of another group, refers to a carbon atom double-bonded to an oxygen atom (C^O). The term "oxo", as employed herein as such or as part of another group, refers to oxygen atom linked to another atom by a double bond (=0). The term "hydroxy C1-7 alkyl", as employed herein, refers to at least one hydroxy group, as defined herein, appended to the parent molecular moiety through a C1-7 alkyl group, as defined herein. Representative examples of hydroxyl C1-7 alkyl include, but are not limited to, hydroxymethyl, 2,2-dihydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 1-hydroxypropyl, 1-methyl-1-hydroxyethyl and 1-methyl-l- hydroxypropyl. The term "halo C1-7 alkyl", as employed herein, refers to at least one halogen, ias defined herein, appended to the parent molecular moiety through a C1-7 alkyl group, as defined herein. Representative examples of halo C1-7 alkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-chloroethyl and 3- bromopropyl. 1 The term "C3-10 cycloalkyl C1-7 alkyl", as employed herein refers to a C3-10 cycloalkyl group, as defined herein, appended to the parent molecular moiety through a C1-7 alkyl group, as defined herein. The term "phenyl C1-7 alkyl", as employed herein, refers to at least one phenyl group appended to the parent molecular moiety through a C1-7 alkyl group, as defined herein. The term "halo phenyl C1-7 alkyl", as employed herein, refers to at least one halo group appended to the parent molecular moiety through a phenyl C1-7 alkyl group, as defined herein. 1 The term "aryl", as employed herein, refers to a monocyclic, bicyclic or polycyclic aromatic hydrocarbon ring system of 6 to 14 carbon atoms. Examples of. aryl groups include, but are not limited to phenyl, naphthyl, biphenyl, anthryl, biphenylenyl, and acenaphthyl. Preferred aryl group is phenyl. 1 The term "aryl C 1.7 alkyl", as employed herein, refers to at least one aryl group appended to the parent molecular moiety through a C1-7 alkyl group, as defined herein. Examples of aryl C1-7 alkyl groups include, but are not limited to benzyl, benzhydryl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, 1- naphthylmethyl and 2-naphthylmethyl. Preferred aryl C1-7 alkyl group is phenyl C1-7 lalkyl. The term "aryl C2-7alkenyl", as employed herein, refers to an aryl group appended to the parent molecular moiety through a C2-7alkenyl group, as defined herein. Examples of aryl C1-7alk.enyl groups include, but are not limited to 1-phenyl- ethenyl, 2-phenylethenyl and 2-phenylprop-l-enyl. The term "aryl halo C1-7 alkyl", as employed herein, refers to at least one aryl group, as defined herein, appended to the parent molecular moiety through a halo C1-7 alkyl group, as defined herein. Examples of aryl halo C1-7 alkyl groups include, but are not limited to phenyl fluoro methyl and 1-phenyl 2-chloro ethyl. The term "heterocyclyl" includes the definitions of "heterocycloalkyl" and "heteroaryl". The term "heterocycloalkyl" refers to a non-aromatic, saturated or partially saturated, monocyclic or polycyclic ring system with 3 to 10 ring atoms of which at least one, preferably 1-4, is a heteroatom selected from the group consisting of O, N, and S. One particular embodiment of "heterocycloalkyl" is a non-aromatic, saturated or partially saturated, monocyclic or polycyclic ring system with 5 to 10 ring atoms of which 1-4 are heteroatoms selected from the group consisting of N, O and S. Examples of heterocycloalkyl groups include piperdinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,3-dioxolanyl and 1,4-dioxanyl. The term "heteroaryl" refers to a monocyclic, bicyclic, or polycyclic aromatic ring system of 5-14 ring atoms containing at least one, preferably 1 to 4, heteroatom selected from the group consisting of N, O and S. One particular embodiment of "heteroaryl" is a monocyclic, bicyclic, or polycyclic aromatic ring with 5-10 ring atoms of which 1-4 are heteroatoms selected from the group consisting of N, O and S. Examples of 5-10 membered heteroaryl groups include furan, thiophene, indole, azaindole, oxazole, thiazole, thiadiazole, isoxazole, isothiazole, imidazole, 1H- indazole N-methylimidazole, pyridine, pyrimidine, pyrazine, pyrrole, N-methyl- pyrrole, pyrazole, N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4-triazole, 1-methyl-1,2,4- triazole, lH-tetrazole, 1,2,3,4-tetrahydroisoquinoline 1-methyltetrazole, benzoxazole, benzothiazole, benzofuran, benzisoxazole, benzimidazole, 3-quinuclidine, 3,4- dihydroisoquinolin-l(2H)-one, N-methylbenzimidazole, azabenzimidazole, indazole, quinazoline, quinoline, and isoquinoline. Examples of bicyclic heteroaryl groups include those where a phenyl, pyridine, pyrimidine or pyridazine ring is fused to a 5 or 6-membered monocyclic heterocyclyl ring having one or two nitrogen atoms in the ring, one nitrogen atom together with either one oxygen or one sulfur atom in the ring, or one 0 or S ring atom. The term "4-12 membered monocyclic or bicyclic ring containing 0-4 iheteroatoms" refers to a 4-12 membered monocyclic or bicyclic aromatic or non- aromatic cyclic ring in which 0-4 of the ring carbon atoms have been independently replaced with N, O or S. Representative examples of such rings include, but are not limited to phenyl, pyridine, pyrimidine, morpholine, piperidine, piperazine, imida- zole, pyrazole, pyrrole, thiophene, cyclopropyl, 2,3dihydrobenzo[b][l,4]dioxine, 1,2,3,4-tetrahydroisoquinoline, quinoline, indazole, [l,2,4]triazolo[4,3-a]pyridine and tetrahydroisoquinoline. A particular embodiment of "4-12 membered monocyclic or bicyclic ring containing 0-4 heteroatoms" are a monocyclic or bicyclic aromatic or non-aromatic cyclic ring with 5-10 ring atoms of which 0-4 are heteroatoms selected from a group consisting of N, O and S. The term "5-10 membered heterocyclic ring having 1-4 heteroatoms selected from O, N, or S" refers to aromatic, saturated or partially saturated monocyclic, bicyclic or polycyclic ring which have 5 to 10 ring member atoms of which 1 to 4 are heteroatoms selected from a group consisting of O, N, and S. The term "9-12 membered heterocyclic ring having 1-3 heteroatoms selected from N or O" refers to aromatic, saturated or partially saturated monocyclic, bicyclic ... or polycyclic ring which have 9 to 12 ring member atoms of which 1 to 3 are heteroatoms selected from a group consisting of N and O. The term "optionally substituted or substituted", if not otherwise specified, means that at least one hydrogen atom of the optionally substituted group has been substituted with suitable groups as exemplified but not limited to halogen, nitro, cyano, hydroxy, oxo (=0), thio (=S), -N(C,-3alkyl)C(O)(Cr7alkyl), -NHC(O)(C,-7 lalkyl), -NHC(O)(cycloalkyl), -NHC(O)(aryl), -NHC(O)(heterocyciyl), -NHC(O)(heteroaryl), -NHC(O)H, -C(O)NH2, -C(O)NH(C,-7alkyl), -C(O)NH(cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(heteroaryl), -C(O)N(C,-7 alkyl)(Cr7alkyl),.-S(O)NH(Cr7alkyl)!-S(O)2NH(C1-7alkyl),-S(O)NH(cycloalkyl), -S(O)2NH(cycloalkyl), carboxy, -C(O)0(C,-7alkyl),.-C(O)(C,-7alkyl), =N-OH, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkenylalkyl, cycloalkenyl, amino, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclic ring. One particular embodiment of "optionally substituted or substituted" is 1-3 substituents selected from the group consisting of C1-7 alkyl, C3-7 cycloalkyl, halogen, nitro, cyano, amino, hydroxy, halo C1-7 alkyl, hydroxy Cr7 alkyl, C1-7 alkoxy and halo C1-7 alkoxy substituents. As used herein, the terms "treat", "treating" or "treatment" encompass either or both responsive and prophylaxis measures, e.g. measures designed to inhibit or delay the onset of the disease or disorder, achieve a full or partial reduction of the symptoms or disease state, and/or to alleviate, ameliorate, lessen, or cure the disease or disorder and/or its symptoms. The terms "treat," "treating" or "treatment", include, but are not limited to, prophylactic and/or therapeutic treatments. As used herein the terms "subject" or "patient" are well-recognized in the art, and, are used interchangeably herein to refer to a mammal, including dog, cat,-rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, most preferably, a human. In some embodiments, the subject is a subject in need of treatment or a subject with a disease or disorder. However, in other embodiments, the subject can be a normal subject. The term does not denote a particular age or sex. Thus, adult and new-born subjects, whether male or female, are intended to be covered. As used herein the term "therapeutically effective amount," refers to a sufficient amount of a compound or a composition being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other'desired alteration of a biological system. The term "therapeutically effective amount" includes, for example, a prophylactically effective amount. "Pharmaceutically acceptable" means that, which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use. "Pharmaceutical ly acceptable salt" refers to the salts of the compounds, that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Such salts include: acid addition salts, formed with inorganic acids such as hydro- chloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methane sulfonic acid, ethane sulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethane- sulfonic acid, benzene sulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalene- sulfonic acid, 4-toluenesulfonic acid, camphor sulfonic acid, 4-methylbicyclo[2.2.2]- oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethyl- acetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxyl naphthoic acid, salicylic acid, stearic acid, muconic acid, and the like. The term "stereoisomers" refers to any enantiomers, diastereomers, or geometrical isomers of the compounds of formula (I) wherever they are chiral or when they bear one or more double bond. When the compounds of the formula (I) and related formulae are chiral, they can exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis. In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids, such as the R and S forms of tartaric acid, diacetyl tartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (for example N-benzoylproline or N-benzenesulfonylproline), or the various optically active camphorsulfonic acids. Also advantageous is chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel). Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, such as, for example, hexane/isopropanol/ acetonitrile, for example in the ratio 82:15:3. Bromodomain inhibitors are believed to be useful in the treatment of a variety of diseases or conditions related to systemic or tissue inflammation, inflammatory responses to infection or hypoxia, cellular activation and proliferation, lipid metabolism, fibrosis and in the prevention and treatment of viral infections. Bromodomain inhibitors may be useful in the treatment of a wide variety of chronic autoimmune and inflammatory conditions such as rheumatoid arthritis, osteoarthritis, acute gout, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease (Crohn's disease and Ulcerative colitis), asthma, chronic obstructive airways disease, pneumonitis, myocarditis, pericarditis, myositis, eczema, dermatitis, alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis, athero- sclerosis, Alzheimer's disease, depression, retinitis, uveitis, scleritis, hepatitis, pancreatitis, primary biliary cirrhosis, sclerosing cholangitis, Addison's disease, hypophysitis, thyroiditis, type Idiabetes and acute rejection of transplanted organs. Bromodomain inhibitors may be useful in the treatment of a wide variety of acute inflammatory conditions such as acute gout, giant cell arteritis, nephritis including lupus nephritis, vasculitis with organ involvement such as glomerulo- nephritis, vasculitis including giant cell arteritis, Wegener's granulomatosis, Polyarteritisnodosa, Behcet's disease, Kawasaki disease, Takayasu's Arteritis, 'vasculitis with organ involvement and acute rejection of transplanted organs. Bromodomain inhibitors may be useful in the prevention or treatment of diseases or conditions which involve inflammatory responses to infections with bacteria, viruses, fungi, parasites or their toxins, such as sepsis, sepsis syndrome, septic shock, endotoxaemia, systemic inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome, toxic shock syndrome, acute lung injury, ARDS (adult respiratory distress syndrome), acute renal failure, fulminant hepatitis, burns, acute pancreatitis, post-surgical syndromes, sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis, malaria and SIRS associated with viral infections such as influenza, herpes zoster, herpes simplex and coronavirus. Bromodomain inhibitors may be useful in the prevention or treatment of conditions associated with ischaemia-reperfusion injury such as myocardial infarction, cerebro- vascular ischaemia (stroke), acute coronary syndromes, renal reperfusion injury, organ transplantation, coronary artery bypass grafting, cardio- pulmonary bypass procedures, pulmonary, renal, hepatic, gastro-intestinal or peripheral limb embolism. Bromodomain inhibitors may be useful in the treatment of disorders of lipid metabolism via the regulation of APO-A1 such as hypercholesterolemia, atherosclerosis and Alzheimer's disease. Bromodomain inhibitors may be useful in the treatment of fibrotic conditions such as idiopathic pulmonary fibrosis, renal fibrosis, post-operative stricture, keloid formation, scleroderma and cardiac fibrosis. Bromodomain inhibitors may be useful in the prevention and treatment of viral infections such as herpes virus, human papilloma virus, adenovirus and pox- virus and other DNA viruses. Bromodomain inhibitors may be useful in the treatment of cancer, including hematological, epithelial including lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and neurological tumours. In one embodiment the disease or condition for which a bromodomain inhibitor is indicated is selected from diseases associated with systemic inflammatory response syndrome, such as sepsis, burns, pancreatitis, major trauma, haemorrhage and ischaemia. In this embodiment the bromodomain inhibitor would be administered at the point of diagnosis to reduce the incidence of: SIRS, the onset of shock, multi-organ dysfunction syndrome, which includes the onset of acute lung injury, ARDS, acute renal, hepatic, cardiac and gastro-intestinal injury and mortality. In another, embodiment the bromodomain inhibitor would be administered prior to surgical or other procedures associated with a high risk of sepsis, haemorrhage, extensive tissue damage, SIRS or MODS (multiple organ dysfunction syndrome). In a particular embodiment the disease or condition for which a bromodomain inhibitor is indicated is sepsis, sepsis syndrome, septic shock and endotoxaemia. In another embodiment, the bromodomain inhibitor is indicated for the treatment of acute or chronic pancreatitis. In another embodiment the bromodomain is indicated for the treatment of burns. In one embodiment the disease or condition for which a bromodomain inhibitor is indicated is selected from herpes simplex infections and reactivations, cold sores, herpes zoster infections and reactivations, chickenpox, shingles, human papilloma virus, cervical neoplasia, adenovirus infections, including acute respiratory disease, poxvirus infections such as cowpox and smallpox and African swine fever virus. In one particular embodiment a bromodomain inhibitor is indicated for the treatment of Human papilloma virus infections of skin or cervical epithelia. The term "diseases or disorders where bromodomain inhibition is desired", is intended to include each of or all of the above disease states. While it is possible that for use in therapy, a compound of formula (I) as well as pharmaceutically acceptable salts thereof may be administered as such, it is common to present the active ingredient as a pharmaceutical composition. The compounds and pharmaceutically compositions of the present invention may be used in combination with other drugs that are used in the treatment/- prevention/suppression or amelioration of the diseases or conditions for which compounds of the present invention may be useful. Such other drugs may be administered, by a route and in an amount commonly used there for. simultaneously or sequentially with a compound of the present invention. When a compound of the present invention is used simultaneously with one or more other drugs, a pharma- ceutical composition containing such other drugs in addition to the compound of the present invention may also be preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention. A pharmaceutical composition of the invention may be formulated as being compatible with its intended route of administration, which may preferably be an oral administration. For example the pharmaceutical compositions of the invention may be formulated for administration by inhalation, such as aerosols or dry powders; for oral administration, such in the form of tablets, capsules, gels, syrups, suspensions, emulsions, elixirs, solutions, powders or granules; for rectal or vaginal administration, such as suppositories; or for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular, or infusion) such as a sterile solution, suspension or emulsion. The compounds of the present invention may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethyl cellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano- particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980). The novel spiro[cyclobutane-1,3'-indolin]-2'-one derivatives of formula (I) according to the present invention may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimization procedures. The details of the processes according to the present invention are given in the example section mentioned below. In a further aspect, the compounds of the present invention can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the present invention also embraces isotopically- labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses. Exemplary isotopes that can be incorporated in to compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as 2H ("D"), 3H, UC, 13C, 14C, 13N, 15N, 150,170, 180,32P, 33P, 3SS, 18F, 36C1,123I and 125I. Isotopically labeled compounds of the present inventions can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. The abbreviations used in the entire specification may be summarized herein below with their particular meaning. MeOH - Methanol, EtOH - Ethanol, DCM - Dichloromethane, DMF - N, N-Dimethyl formamide, DMSO -DimethySulfoxide, CDC13-Deuterated chloroform, EtOAc - Ethyl acetate, CH3CN-Acetonitrile, TH.F - Tetrahydrofuran, TEA - Triethylamine, DIPEA-Diisopropylethylamine, TFA-Trifluoroacetic acid, AcOH-Acetic acid, AlCl3-Aluminium chloride, NBS-N-bromosuccinimide, PyBOP- (Benzotriazol-l-yloxy)tripyrrolidino phosphonium hexafluorophosphate, HATU-(1- [Bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafiuorophosphate), DMF.DMA-N,N-Dimethylformamide dimethyl acetal, NMO- N-methyl morpholine N-oxide, DCE-1.2-Dichloro ethane, CFL-Compact fluorescent lamp, KOAc-Potassium acetate, Na2S04-Sodium sulphate, H2SO4 - Sulfuric acid, HN03-Nitric acid, NaHC03-Sodiumbicarbonate, Na2C03 - Sodium carbonate, K2CO3 - Potassium carbonate, Cs2C03-Cesium carbonate, NaH-Sodium hydride, DAST- Diethyl amino sulfur trifluoride, NaBH4-Sodiumborohydride, NaCNBH3-Sodium cyanoborohydride, (BOC) 20-Di-tert-butyl dicarbonate, EDC.HCl-l-Ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride, HOBt-1-hydroxybenzotriazole, AcCl-Acetyl chloride, Ac20-Acetic anhydride, NH4Cl-Ammonium chloride, H20- water, NaOMe-Sodium methoxide, NaOH - Sodium hydroxide, HC1 - Hydrochloric acid, Pd (pph3)4 -Tetrakis (triphenylphosphine) palladium (O), Pd (dppf) Cl2- [1,1- Bis(diphenyl phosphino)ferrocene]dichloropalladium(II), complex with dichloromethane, Pd(OAc)2-Palladium (II) acetate, Pd/C - Palladium on activated carbon, TLC - Thin layer chromatography, RT-Room temperature, N - Normality, M- Molarity, s- Singlet, d- Doublet, t- Triplet, m- Multiple:, 1HNMR - Proton nuclear magnetic resonance, MS - Mass spectroscopy, HPLC-High-performance liquid chromatography, LC - Liquid chromatography, H - Proton, MHz - Mega hertz, Hz - Hertz, Ppm - Parts per million, Bs - Broad singlet, ES - Electro spray. Although the invention has been illustrated by following examples, it is not to be construed as being limited thereby. Various modifications and embodiments can be made without departing from the spirit and scope thereof. The MS data provided in the examples described below were obtained as follows: Mass spectrum: LC/MS Agilent 6120 Quadrapole LC/MS. The NMR data provided in the examples described below were obtained as follows: 'H-NMR: Varian 400 MHz. The microwave chemistry was performed on a CEM Explorer. The procedure for the compounds of formula (I) are detailed herein below stepwise including the general synthesis of various intermediates involved in process of synthesis of the compounds according to the present invention. Examples Step-a: N'-phenylcyclobutanecarbohydrazide (la): i To a solution of phenyl hydrazine hydrochloride (60 g, 416.6 mmol) in DMF (200 mL) at -30 °C were added pyridine (100 mL, 1249.8 mmol) followed by cyclobutanecarbonylchloride (47.3 mL, 416.6 mmol) dropwise. The mixture was stirred at -30 °C for 2 h. The mixture was poured into ice cooled water and the solid formed was filtered off, washed with water and dried under reduced pressure to 'afford the title product as white solid. Yield 50.0 g (63%).'H NMR (400 MHz, DMSO-A): 5 9.47 (s, 1H), 7.13-7.09 (m, 2H), 6.70-6.63 (m, 3H), 3.12-3.08 (m, 1H), 2.20-2.06 (m, 4H), 1.96-1.77 (m, 2H); LC-MS: m/zl9l.2 (M+H)+. Step-b: Spiro[cyclobutane-1.3'-indolin]-2'-one (lb): To a solution of N'-phenylcyclobutanecarbohydrazide (15 g, 78.9 mmol) in quinoline (15 mL) was added calcium oxide (44.2 g, 789.0 mmol). The mixture was heated to 260 °C on pre-heated sand bath and stirred for. 4 h. The mixture was cooled to RT and quenched with 6 N HC1 dropwise. The mixture was extracted with EtOAc (250 ml x 2). The combined organic layer was washed with water (200 mL), brine (200 mL), dried over sodium sulphate and concentrated under reduced pressure. The 'residue was purified on silica gel (60-120 mesh) to afford the title product as yellow solid 8.0 g (58%).'H NMR (400 MHz, DMSO-^): 5 10.20 (s, 1H), 7.54 (d,J=7.4 Hz, 1H), 7.15 (t, J=7.3 Hz, 1H), 6.99 (t, J=7.4 Hz, 1H), 6.77 (d, J =7.8 Hz, 1H), 2.44- 2.38 (m, 2H), 2.30-2.22 (m, 4H); LC-MS: m/z 174.1 (M+H)+. Step-c: 5'-nitrospiro[cyclobutane-1.3'-indolin]-2'-one (lc): i To a stirring suspension of spiro[cyclobutane-1,3'-indolin]-2'-one (4.0 g, 23.12 mmol) in sulphuric acid (40 mL) at -20 °C was added potassium nitrate (2.3 g, 23.12 mmol) portion wise. The mixture was stirred at -20 °C for 30 min. The mixture was poured into ice cooled water and the solid formed was filtered off, washed with water and dried under reduced pressure and purified under column to afford title compound as yellow solid 2.0 g (40 %).'H NMR (400 MHz, DMSO-d6): 5 10.95 (s, 1H), 8.44 (d, J=2.5 Hz, 1H), 8.15(dd, J=2.1 Hz & 8.5 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 2.46-2.38 (m, 4H), 2.27-2.17 (m, 2H ); LC-MS: m/z 217.1 (M-H)". Step-d: 7'-bromo-5'-nitrospiro[cvclobutane-1.3'-indolin]-2'-one (Id): To a stirring suspension of 5'-nitrospiro[cyclobutane-1,3'-indolin]-2'-one (3.0 g, 13.76 mmol) in sulphuric acid (20 mL) at RT was added N-bromosuccinimide (2.9 g, 16.51 mmol) portion wise. The mixture was stirred at RT for 16 h. The mixture was poured into ice cooled water and the solid formed was filtered off, washed with water and dried under reduced pressure to afford title compound as pale brown solid 2.8 g (70 %).lU NMR (400 MHz, DMSO-^s) 5 11.27 (s, 1H), 8.46 (d, .7=2.1 Hz, 1H), 8.30 (d, J=1.9 Hz, 1H), 2.48-2.41 (m, 4H), 2.25-2.19 (m, 2H); LC-MS: m/z 297 (M+H)+. Step-e: 5'-amino-7'-bromospiro[cyclobutane-1.3'-indolin]-2'-one (le): To a solution of 7'-bromo-5'-nitrospiro[cyclobutane-1,3'-indolin]-2'-one (2.8 g, 9.45 mmol) in EtOH (30 mL) and H20 (15 mL) were added iron powder (2.6 g, 47.25 mmol) and NH4C1 (2.5 g, 47.25 mmol). The mixture was heated to 100 °C for 3 h. The mixture was cooled to RT, filtered through celite and washed with EtOAc. The combined filtrate was concentrated. The residue was diluted with water, extracted with EtOAc (100 mL), washed with brine (100 mL), dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as yellow solid 2.5 g (49%);'H NMR (400 MHz, DMSO-^) 5 10.04 (s, 1H), 6.82 (d, J=2.0 Hz, 1H), 6.55 (d, J=2.0 Hz, 1H), 4.98 (s, 2H), 2.44-2.39 (m, 2H), 2.22-2.07 (m 4H); LC-MS: m/z 267.5 (M+H)+. Step-f: N-(7'-bromo-2'-oxospiro[cyclobutane-1.3'-indolin]-5'-yl)-2.4-difluoro benzenesulfonamide (Intermediate 1): To an ice cooled solution of 5'-amino-7'-bromospiro[cyclobutane-1,3'- indolin]-2'-one(2.3 g, 8.61 mmol) in DCM (30 mL) were added pyridine (4.2 mL, 51.66 mmol) followed by 2,4-difluorobenzenesulfonyl chloride (1.3 mL,9.47 mmol) dropwise. The mixture was stirred at RT for 2 h. The mixture was diluted with DCM (100 mL), washed with water (100 mL) and brine (100 mL), dried over sodium sulphate and concentrated under reduced pressure and column purified to afford the title compound as off white solid (1.8 g, 48%).1HNMR (400 MHz, DMSO-d6): 5 10.54 (s, 1.H), 10.51 (s; 1H), 7.89- 7.83 (m, 1H), 7.59-7.53 (m, 1H), 7.28-7.23 (m, 2H), 7.02 (d, J=l.5 Hz, 1H), 2.44-2.33 (m, 2H), 2.23-2.03 (m, 4H); LC-MS: m/z 445.0 (M+3H)3+. The below intermediates 2 and 3 were prepared according to the procedure depicted in step-f of intermediate-1 by using 5'-amino-7'-bromospiro[cyclobutane- 1,3'-indolin]-2'-one as a starting compound and in presence of appropriate reactants, reagents, solvents and in appropriate conditions. The characterization data for the intermediates are detailed in below table. Intermediate-4: 2.4-difluoro-N-f7'-nitro-2'-oxospiro[cyclobutaiie-13'-indolin]-5'- yl)benzenesulfonamide: Step-a: Synthesis of 5'-aminospiro[cyclobutane-1.3'-indolin]-2'-one (4a): The compound was prepared using the procedure of step-e of Intermediate-1. 'H NMR (400 MHz, DMSO-&): 5 9.77 (s, 1H), 6.82 (d, J=2.0 Hz, 1H), 6.47 (d, 7=7.8 Hz, 1H), 6.39-6.36 (m, 1H), 4.69 (s, 2H), 2.44-2.37 (m, 2H), 2.20-2.00 (m, 4H); LC-MS: m/z 189.2 (M+l)+. Step-b: 2-(2'-oxospiro[cyclobutane-1.3'-indolin]-5'-yl)isoindoline-1.3-dione (Mi To a solution of 5'-aminospiro[cyclobutane-1,3'-indolin]-2'-one (3.6 g, 18.99 mmol) in AcOH (35 mL) was added pthalic anhydride (4.2 g, 20.48 mmol). The mixture was heated to 100 °C for 2 h. The mixture was poured into crushed ice and the solid formed was filtered off, washed with water and dried under reduced pressure to afford the title product as brown solid (4.5 g, 75%).'H NMR (400 MHz, DMSO-J*): 5 10.43 (s, 1H), 7.98-7.90 (m, 4H), 7.33 (d, 7=1.9 Hz, 1H), 7.24-7.21 (m, 1H), 6.92 (d, J=8.3 Hz, 1H), 2.48-2.43 (m, 2H), 2.32-2.14 (m, 4H); LC-MS: m/z 319.1 (M+l)+. Step-c: 2-(7'-nitro-2'-oxospiro[cyclobutane-1.3'-indolin]-5'-yl)isoindoline-1.3- dione (4c): To a solution of 2-(2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yl)isoindoline- 1,3-dione (9.2 g, 28.93 mmol) in AcOH (100 mL) at RT was added nitric acid (9.0 m.L) dropwise. The mixture was heated to 110 °C for 2 h. The mixture was poured into ice cooled water and the solid formed was filtered off, washed with water and dried under reduced pressure to afford title compound as brown solid (10.5 g). 'H NMR(400 MHz, DMSO-40: 5 10.19 (s, 1H), 8.15 (d, J=1.5 Hz, 1H), 8.13 (d, J=1.5 Hz, 1H), 8.02-7.93 (m, 4H), 2.51-2.48 (m, 2H), 2.39-2.37 (m, 4H); LC-MS: m/z 364.1 (M+l)+. Step-d: 5'-amino-7'-nitrospiro[cyclobutane-1.3'-indolin]-2'-one (4dV To a solution of 2-(7'-nitro-2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yl)iso- indoline-1,3-dione (10.5 g, 28.92 mmol) in EtOH (100 mL) was added hydrazine hydrate (21 mL) and then heated to 100 °C for 2h. Reaction mixture was poured into ice cooled water and the solid formed was filtered off, washed with water and dried under reduced pressure to afford the title compound (5.5 g). 'H NMR (400 MHz, DMSO-J5): 5 10.52 (s, 1H), 7.30 (d, J=2.0 Hz, 1H), 7.11 (d, J=1.9 Hz, 1H), 5.38 (s, 2H), 2.54-2.48 (m, 2H), 2.48-2.14 (m, 4H); LC-MS: m/z234.\ (M+l)+. Step-e: Synthesis of2.4-difluoro-N-f7'-nitro-2'-oxospiro[cyclobutane-l .3'- indolin]-5'-yl)benzenesulfonamide (Intermediate-4): To an ice cooled solution of 5'-amino-7'-nitrospiro[cyclobutane-1,3'-indolin]- 2'-one (2.0 g, 8.58 mmol) in DCM (20 mL) were added pyridine (1.4 mL, 17.16 mmol) followed by 2,4-difluorobenzenesulfonyl chloride (1.7 mL, 12.87 mmol) dropwise. The mixture was at RT for 3 h. The mixture was diluted with DCM (100 mL), washed with water (100 mL) and brine (100 mL), dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as yellow solid (2.5 g, 89 %.).'HNMR(400 MHz, DMSO-^): 5 11.0 (s, 1H), 10.86 (s, 1H), 7.95- 7.83 (m, 1H), 7.68 (d, J=1.5 Hz, 1H), 7.62 (d, 7=1.5 Hz, 1H), 7.56 (t, J=8.8 Hz, 1H), . 7.30-7.25 (m, 1H), 2.47-2.40 (m, 2H), 2.35-2.12 (m, 4H). Intermediate-5: Methyl 5'-amino-2'-oxospiro[cyclobutane-L3'-indoline]-7'- carboxylate: Step-(a): Methyl 5'-nitro-2'-oxospiro[cyclobutane-1.3'-indoline]-7'- carboxylate f5a): To a solution of 7'-bromo-5'-nitrospiro[cyclobutane-1,3'-mdolin]-2'-one (1.0 g, 3.37 mmol) in triethyl amine (30 mL) were added xantphos (0.19 g, 0.337 mmol), palladium(ll)acetate (0.15 g, 0.674) and methanol (4 mL). The mixture was purged with carbon monoxide gas for 10 min and then heated to 80 °C for 16 h under carbon monoxide atmosphere. The mixture was diluted with EtOAc (100 mL) and washed with IN HC1 (100 mL), water (100 mL) and brine (100 mL), dried over sodium sulphate and concentrated under reduced pressure and column purified to afford the title compound as yellow solid (0.45 g, 48%.). 'H NMR (400 MHz, DMSO-ck): 5 10.87 (s, 1H), 8.66 (d, J=2A Hz, 1H), 8.53(d, J=2.5 Hz, 1H), 3.90 (s, 3H), 2.45-2.32 (m, 4H), 2.28-2.16 (m, 2H); LC-MS: m/z 277.1 (M+H)+. Step-(bV Methyl 5'-amino-2'-oxospiro[cyclobutane-1.3'-indoline]-7'- carboxylate (Intermediate 5): The compound was prepared using the procedure of step-e of Intermediate-1. 'H NMR (400 MHz, DMSO-4s): 5 9.67 (s, 1H), 7.11 (d, J=2.5 Hz, 1H), 6.93(d, .7=2.4 Hz, 1H), 5.03 (s, 2H), 3.80 (s, 3H), 2.46-2.40 (m, 2H), 2.26-2.12 (m, 4H); LC-MS: m/z 247.2 (M+H)+. Intermediate-6: 5'-amino-N-(l-methylpiperidin-4-ylV2'-oxospiro[cyclobutane-1.3'- indoline]-7'-carboxamide Step a: 5'-nitro-2'-oxospiro[cvclobutane-1.3'-indo]ine]-7'-carboxylic acid (6a) To a solution of methyl 5'-nitro-2'-oxospiro[cyclobutane-1,3'-indoline]-7'- carboxylate (0.35 g, 1.27 mmol) in THF (4 mL) was added lithium hydroxide monohydrate (0.21 g, 5.08 mmol) in 2 mL of water. The mixture was stirred at RT for 16 h. The mixture was concentrated, diluted with water, acidified with IN HC1 and extracted with EtOAc (100 mL), washed with brine (100 mL), dried over sodium sulphate and concentrated under reduced pressure to afford the solid title compound (0.2 g, 60%). 'HNMR (400 MHz, DMSO-Jd): 5 13.80 (bs, 1H), 10.56 (s, 1H), 8.63 (d, J=2.4 Hz, 1H), 8.51 (d, J=2.4 Hz, 1H), 2.56-2.50 (m, 2H), 2.49-2.41 (m,. 2H), 2.31-2.20 (m, 2H); LC-MS: m/z 263.1 (M+H)+. Step-b: N-(l-methylpiperidin-4-ylV5'-nitro-2'-6xospiro[cyclobutane-1.3'- indoline]-7'-carboxamide (6bV To a solution of 5'-nitro-2'-oxospiro[cyclobutane-1,3'-indoline]-7'-carboxylic acid (0.2 g, 0.76 mmol) in DCM (10 mL) were added l-methylpiperidin-4-amine (0.14 mL, 1.14 mmol), HOBt (0.15 g, 1.14 mmol), EDC.HC1 (0.22 g, 1.14 mmol) and diisopropyl ethylamine (0.4 mL, 2.29 mmol). The mixture was stirred at RT for 16 h. The mixture was poured into ice water and solids were filtered off. The mixture was then washed with water and dried under reduced pressure to afford the solid title compound (0.18 g, 66%). 'HNMR (400 MHz, DMSO-^6): 5 10.19 (bs, 1H), 8.86 (bs, 1H), 8.65 (d, J=2.0 Hz, 1H), 8.54 (d, J=1.9 Hz, 1H), 3.81-3.70 (m, 1H), 2.86-2.82 (m, 2H), 2.47-2.42 (m, 4H), 2.38-2.24 (m, 2H), 2.23 (s, 3H), 2.18-2.03 (m, 2H), 1.83-1.80 (m32H), 1.66-1.55 (m, 2H); LC-MS: m/z 359.1 (M+H)+. Step-c: 5'-amino-N-fl-methylpiperidin-4-ylV2'-oxospiro[cyclobutane-1.3'- indoline]-7'-carboxamide (Intermediate-6). The compound was prepared using the procedure of step-e of Intermediate-1. 'H NMR (400 MHz, DMSO-4,): 5 9.23 (s, 1H), 8.17 (d, J=7.8 Hz, 1H), 7.01 (d, 7=1.9 Hz, 1H), 6.78 (d, J=1.9 Hz, 1H), 4.95 (bs, 2H), 3.76-3.66 (m, 1H), 2.85-2.82 (m, 2H), 2.45-2.39 (m, 2H), 2.23 (s, 3H), 2.23-2.07 (m, 6H), 1.78-1.74 (m, 2H), 1.63-1.57 (m,2H); LC-MS: m/z 329.2 (M+H)+. Intertnediate-7: 7'-amino-5'-bromospiro[cyclobutane-1.3'-indolin]-2'-one Step-(a): 5'-bromospiro[cyclobutane-L3'-indolin]-2'-one (7a): To a solution of spiro[cyclobutane-1,3'-indolin]-2'-one (5.0 g, 28.73 mmol) in acetonitrile (50 mL) at RT was added N-bromo succinimide (6.1 g, 34.47 mmol) portion wise. The mixture was stirred at RT for 2 h. The mixture was poured into crushed ice and the solid formed was filtered off. The mixture was washed with water and dried under reduced pressure to afford the title compound as off white solid (6.1 g). 'H NMR (400 MHz, DMSO-^j): 510.34 (s, 1H), 7.75 (d, J=2.0 Hz, 1H), 7.33 (dd, J;=2.0 Hz, J2=83 Hz, 1H), 6.74 (d, .7=8.1 Hz, 1H), 2.40-2.31 (m, 4H), 2.28-2.16 (m, 2H); LCMS: m/z 253.0 (M+H)+. Step-(b): 5'-bromo-7'-nitrospiro[cyclobutane-1.3'-indolin]-2'-one f7b): The compound was prepared using the procedure of step-c of Intermediate-1. 'HNMR (400 MHz, DMSO-^): 511.15 (s, 1H), 8.22 (d, J=1.4 Hz, 1H), 8.09 (d, 7=1.9 Hz, 1H), 2.46-2.42 (m, 4H),.2.24-2.20 (m, 2H); LCMS: m/z 296.0 (M+H)+. Step-(c): 7'-amino-5'-bromospiro[cyclobutane-1.3'-indolin]-2'-one (Intermediated: The compound was prepared using the procedure of step-e of Intermediate-1. 'H NMR (400 MHz, DMSO-Jtf): 5 9.81 (s, 1H), 6.96 (d, J=l .5 Hz, 1H), 6.68 (d, /=2.0 Hz, 1H), 5.08 (s, 2H), 2.41-2.35 (m, 2H), 2.28-2.22 (m, 2H), 2.19-2.11 (m, 2H); LCMS: m/z 267.0 (M + H)+. Intermediate-8: 5'-amino-7'-cyclopropylspiro[cyclobutane-1.3'-indolin]-2'-one Step-a: 7'-cyclopropyl-5'-nitrospiro[cyclobutane-l.3'-indolin]-2'-one (8a): To a stirred solution of 7'-bromo-5'-nitrospiro[cyclobutane-1,3'-indolin]-2'- one (0.200 g, 0.673 mmol) in mixture of solvents 1,4-dioxane (10 mL): water (3 mL) was added potassium phosphate (0.285 g, 1.34 mmol), Pd(amphos)Cl2 (0.047 g, 0.067 mmol) and cyclopropylboronic acid (0.069 g, 0.807 mmol). The mixture was purged with nitrogen gas for 10-15 min and heated to 100-110°C for 12 h under nitrogen atmosphere or in a sealed tube. The mixture was poured into ice cold water (10 mL) and extracted with ethyl acetate. The combined extracts were washed with water, dried over MgSC>4 and evaporated. The obtained crude product was purified by silica gel chromatography using a mixture of 70 % ethyl acetate/hexane as an eluent to get the title compound as a pale yellow solid (0.120 g, 69.36%); LC-MS: 257.0 [M-H] Step-b: 5'-amino-7'-cyclopropylspiro[cyclobutane-1.3'-indolin]-2'-one fIntermediate-8): The process of this, step was adopted from step-c of Intermediate-7 (0.050 g, 51.55%); LC-MS: 229.1 [M+H]+. Intermediate-9: 5'-nitro-7'-(4.4.5.5-tetramethyl-1.3.2-dioxaborolari-2-yl)spiro[cyclo- butane-1.3'-indolin]-2'-one To a solution of 7'-bromo-5,-nitrospiro[cyclobutane-1,3'-indolin]-2'-one (1.0 g, 3.38 mmol) and 4,4,4',4,,5,535,J5'-octamethyl-2,2,-bi(1,3;2-dioxaborolane) (1.76 g, 7.76 mmol) in 1,4-dioxane (20 mL) in sealed tube was added potassium acetate (1.0 g, 10.14 mmol). The reaction mixture was purged with nitrogen gas for 10 min and then Pd(dppf)2Cl2«DCM (0.28 g, 0.39 mmol) was added. The mixture was again purged with nitrogen gas for 5 min and then heated to 100 °C for 16 h. The mixture was diluted with EtOAc (150 mL) and washed with water (150 mL) and brine (150 -40 °C and stirred for 1 h. The mixture was again cooled to -78 °C and 1,1,1- trifluoro-N-phenyl-N-((trifIuoromethyl)sulfonyl)methanesulfonamide (2.9 g, 8.26 mmol) in THF (5 mL)was added over a period of 5 min. The mixture was slowly brought to 0 °C followed by stirring for 4 h, cooling to -78 °C and quenching with 1 mL of MeOH in 10 mL of EtOAc. The mixture was slowly brought to RT and concentrated under reduced pressure. The residue was dissolved in 20 mL of diethyl ether and 20 mL of pentane was added. This organic layer was concentrated under reduced pressure and purified by combi flash to afford the title compound as colorless oil (1.20 g, 57 %). 'HNMR (400 MHz, DMSO-d6): 5 8.88 (d, J=l.9 Hz, 1H), 8.70-8.69 (m, 1H), 8.06-8.04 (m, 1H), 7.59-7.55 (m, 1H), 6.29 (d, J=4.9 Hz, 1H), 5.72 (d, J=4.9 Hz, 1H); LC-MS: m/z 254.1 (M+H)+. Intermediate-11: l-(Pyridin-2-yl)vinyl trifluoromethanesulfonate The process of this step was adopted from Intermediate-10. 'H NMR (400 MHz, DMSO-Jtf): 5 8.68 (d, J=4.4 Hz, 1H), 7.99-7.94 (m, 1H), 7.89-7.87 (m, 1H), 7.52-7.49 (m, 1H), 6.45 (d, J=4.4 Hz, 1H), 5.77 (d, J=4.4 Hz, 1H); LC-MS: m/z 254.1 (M+H)+. The present invention is further exemplified, but not limited, by the following examples that illustrate the preparation of compounds according to the invention. Example-I: 2.4-difluoro-N-(7'-(3-hydroxyphenyl)-2'-oxospiro[cyclobutane-1.3'- indolin]-5'-yl)benzenesulfonamide: (Compound-D lntermediate-1 Compound-1 To a solution of N-(7'-bromo-2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yl)-2,4- difluoro benzenesulfonamide (intermediate-1) (0.15 g, 0.34 mmol) in 1,4-dioxane (8 mL) and H20 (2 mL) were added (3-hydroxyphenyl)boronic acid (0.057 g, 0.41 mmol), potassium phosphate (0.22 g, 1.02 mmol). The mixture was degassed with nitrogen purging for 20 min. Then Pd(Amphos)Cl2(0.024 g, 0.034 mmol) was added and the mixture was heated at 100°C for 16 h. The mixture was concentrated under ireduced pressure and the residue was diluted with EtOAc (100 ml), washed with water (100 mL), brine (100 mL), dried over sodium sulphate and concentrated under reduced pressure and column purified to afford the title compound as white solid (0.07 g, 45%).'1HNMR(400 MHz, DUSO-d6): 5 10.39 (s,lH), 10.04 (s, 1H), 9.51 (s, 1H), 7.88-7.82 (m, 1H), 7.58-7.53 (m, 1H), 7.27-7.19 (m, 3H), 6.82 (d, J=2.0 Hz, HH), 6.75 (dd, Ji=7.8 Hz, J2=1.5 Hz, 1H), 6.69-6.66 (m, 2H), 2.44-2.38 (m, 2H), . 2.24-2.06 (m, 4H); LC-MS: m/z 457.1 (M+H)+. The below compounds were prepared by procedure similar to the one described in Example-I with appropriate variations in reactants, quantities of reagents land reaction conditions. The physiochemical characteristics of the compounds are also summarized. Example-II: N-(7'-amino-2'-oxospiro[cvclobutane-13'-indolin]-5'-yiy2-methoxy- benzenesulfonamide: (Compound-12) To a solution of N-(7'-bromo-2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yi)-2- methoxybenzenesulfonamide (intermediate-2) (0.2 g, 0.46 mmol) in DMSO (1 mL) were added copper(l)iodide (0.009 g, 0.046), L-proline (0.01 g, 0.09 mmol), NaOH (0.03 g, 0.69 mmol) followed by aqueous ammonia (1 mL). The mixture was stirred at 100 °C in sealed tube for 16 h. The mixture was diluted with EtOAc (100 mL) and washed with water (100 mL) and brine (50 mL), dried over sodium sulphate and concentrated under reduced pressure and purified by preparative HPLC to afford the title compound as pale brown solid (0.03 g, 17%.).'H NTvlR (400 MHz, DMSO-tf,,): 5 9.56 (s, 1H), 9.44 (s, 1H), 7.66 (dd, J=1.5 Hz & 7.9 Hz, 1H), 7.54 (t, J=6.9 Hz, 1H), 7.17 (d, .7=7.8 Hz, 1H), 6.98 (t, J=7.3 Hz, 1H), 6.55 (d, J=1.5 Hz, 1H), 6.35 (d, J=1.4 Hz, 1H), 5.0 (bs, 2H), 3.93 (s, 3H), 2.36-2.31 (m, 2H), 2.20-2.00 (m, 4H); LC-MS: m/z374.1(M+H)+. Example-Ill: N-(7'-((cvclopropylmethynamino)-2'-oxospiro[cyclobutane-1.3'- indolin]-5'-yl)-2-methoxybenzenesulfonamide (PI): (Compound-13) and N-(7'-(but- 3-en-l-ylamino)-2'-oxospiro[cyclobutane-1.3'-indolin]-5'-yl)-2- methoxvbenzenesulfonamide (P2): (Compound-14) To a solution of N-(7'-amino-2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yl)-2- methoxy benzenesulfonamide (Compound-12) (0.15 g, 0.4 mmol) in isopropyl alcohol (0.3 mL) was added(bromomethyl)cyclopropane (0.08 mL, 0.8 mmol). The mixture was stirred at 120 °C for 16 h. The mixture was diluted with EtOAc (100 mL), washed with water (100 mL) and brine (50 mL), dried over sodium sulphate and concentrated under reduced pressure and purified by preparative HPLC to afford the title compounds as off white solids PI (0.006 g, 4 %.) & P2 (0.004 g, 2 %). Compound-13 (PI): 'H NMR (400 MHz, DMSO-^): 5 9.71 (s, 1H), 9.41 (s, 1H), 7.68-7.66 (m, 1H), 7.53 (t, J=7.9 Hz, 1H), 7.16 (d, J=8.3 Hz, 1H), 6.97 (t, J=7.8 Hz, 1H), 6.55 (s, 1H), 6.20 (s, 1H), 4.95 (bs, 1H), 3.92 (s, 3H), 2.77-2.75 (m, 2H), 2.33- 2.22 (m, 2H), 2.14-2.0 (m, 4H), 0.93-0.85 (m, 1H), 045 (d, J=7.3 Hz, 2H), 0.17 (d, J=4.4, 2H); ES-MS: m/z 426.5 (M-H)\ Compound-14 (P2): 'H NMR (400 MHz, DMSO-4,): 5 9.64 (s, 1H), 9.43 (s, 1H), 7.67 (dd, .7=1.5 Hz & 7.8 Hz, 1H), 7.55-7.51 (m, 1H), 7.16 (d, .7=7.8 Hz, 1H), 6.98 (t, J=7.4, 1H), 6.56 (d, J=1.4 Hz, 1H), 6.20 (d, .7=1.4 Hz, 1H), 5.86-5.80 (m, 1H), 5.11-5.04 (m, 2H), 4.86 - 4.80 (m, 1H), 3.92 (s, 3H), 2.97-2.95 (m, 2H), 2.33-2.30 (m, 2H), 2.23-2.04 (m, 4H), 2.02-2.00 (m, 2H); ES-MS: m/z 428.3 (M+H)+. Example-IV: N-(7'-amino-2'-oxospiro[cyclobutane-1.3'-indolin]-5'-yl)-2.4-difluoro- benzenesulfonamide: (Compound-15^) To a solution of 2,4-difluoro-N-(7'-nitro-2'-oxospiro[cyclobutane-1,3'-ind6- lin]-5'-yl)benzenesulfonamide (intermediate-4) (6.7 g, 16.38 mmol) in EtOH (70 mL) and H20 (35 mL) were added iron powder (4.6 g, 81.90 mmol) and NH4CI (2.6 g, 49.18 mmol). The mixture was heated to 100 °C for 2 h. The mixture was cooled to RT, filtered through celite and washed with EtOAc. The combined filtrate was concentrated, the residue was diluted with water and extracted with EtOAc (200 mL), washed with brine (200 mL), dried over sodium sulphate and concentrated under reduced pressure and purified to afford the title compound as brown solid (5.8 g, 93%). 'H NMR (400 MHz, DMSO-^s): 5 10.07 (s, 1H), 9.67 (s, 1H), 7.82-7.76 (m, 1H), 7.55-7.50 (m, 1H), 7.25-7.20 (m, 1H), 6.51 (d, J=1.5 Hz, 1H), 6.28 (d, J=2.0 Hz, 1H), 4.93 (s; 2H), 2.38-2.31 (m, 2H), 2.20-1.99 (m, 4H); ES-MS: m/z 378.1 (M- H)". Example-V: 2.4-difluoro-N-(7'-((l-methylpiperidin-3-yl)aminoV2'-oxospiro [cyclobutane-13'-indolin]-5'-y0benzenesulfonamide f Compound-16) i To a suspension of N-(7'-amino-2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yl)- 2,4-difluorobenzenesulfonamide (compound-15) (0.15 g, 0.39 ramol) in titanium isopropoxide (1.5 mL) was added l-methylpiperidine-3-one (0.07 g, 0.59 mmol). The mixture was stirred at RT for 16 h. The mixture was cooled to 0 °C, MeOH (3 mL) was added followed by NaBHt (0.03 g, 0.78 mmol). The mixture was stirred at RT ifor 3 h. The mixture was diluted with EtOAc (100 mL), washed with aqueous ammonia (100 mL) and water (100 mL), dried over sodium sulphate and concentrated under reduced pressure and column purified to afford the title compound as off white solid (0.07 g, 37 %). 'H NMR (400 MHz, DMSO-^j): 5 10.06 (bs, 1H), 9.81 (s, 1H), 7.82-7.76 (in, 1H), 7.53 (t, J=8.8 Hz, 1H), 7.22 (t, J=7.8 Hz, >1H), 6.55 (s, 1H), 6.17(s, 1H), 4.77 (d, J=7.8 Hz, 1H), 3.20-3.15 (m, 1H), 2.70-2.67 (m, 1H), 2.37-2.34 (m, 2H), 2.14 (s, 3H), 2.10-2.05 (m, 4H), 1.98-1.90 (m, 2H), 1.69- 1.65 (m, 3H), 1.49-1.46 (m, 1H), 1.07-1.04 (m, 1H); LC-MS: m/z All.2 (M+H)+. The below compounds were prepared by procedure similar to the one idescribed in Example-V with appropriate variations in reactants, quantities of reagents and reaction conditions. The physiochemical characteristics of the compounds are also summarized. Example-VI: Methyl S'-((2.4-difluorophenyl)sulfonamidoV2'-oxospiro [cyclo- butane-L3'-indoline]-7'-carboxylate (Compound-41') and 5'-ff2.4-difluoro >phenyl)sulfonamido)-2'-oxospiro[cyclobutane-13'-indoline]-7'-carboxylic acid (Compound-42^ Step-fiV Methyl 5'-f(7.4-difluorophenyDsulfonamidoV2'-oxospiro[cyclo- butane-1.3'-indoline]-7'-carboxylate (compound-4P To a solution of N-(7'-bromo-2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yl)-2,4- difluorobenzenesulfonamide (intermediate-1) (0.1 g, 0.23 mmol) in triethyl amine (5 mL) were added xantphos (0.013 g, 0.023 mmol), palladium(ll)acetate (0.01 g, 0.046 mmol) and methanol (0.09 mL, 2.3 mmol). The mixture was purged with carbon monoxide gas for 10 min and then heated to 70 °C for 4 h under carbon monoxide atmosphere. The mixture was diluted with EtOAc (50 mL) and washed with IN HCl (50 mL), water (50 mL) and brine (50 mL). The mixture was dried over sodium sulphate, concentrated under reduced pressure and column purified to afford the title compound as off white solid (0.05 g, 52%). 'HNMR (400 MHz, DMSO-de): 5 10.52 (s, 1H), 10.14 (s, 1H), 7.85-7.81 (m, 1H), 7.57-7.52 (m, 1H), 7.51 (d, 7=2.2 Hz, 1H), 7.38 (d, 7=1.9 Hz, 1H), 7.26-7.23 (m, 1H), 3.81 (s, 3H), 2.42-2.36 (m, 2H), 2.24-2.08 (m, 4H); LC-MS: m/z 423.1 (M+H)+. Step-(ii): 5'-((2.4-difluorophenyl)sulfonamido)-2'-oxospiro[cyclobutane-1.3'- indoline]-7'-carboxylic acid (compound-42^ To a solution of methyl 5'-((2,4-difluorophenyl)sulfonamido)-2'-oxo- spiro[cyclobutane-1,3'-indoline]-7'-carboxylate (0.15 g, 0.35 mmol) in THF (4 mL) was added lithium hydroxide monohydrate (0.044 g, 1.05 mmol) in 1 mL of water. The mixture was stirred at RT for 16 h, concentrated, diluted with water, acidified with IN HCl, extracted with EtOAc (50 mL) and washed with brine (50 mL). The product was dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as off white solid (0.12 g, 82%).'H NMR (400 MHz, DMSO-^s): 5 13.32 (bs, 1H), 10.48 (s, 1H), 9.78 (s, 1H), 7.86-7.78 (m, 1H), 7.58- 7.52 (m, 1H), 7.50 (d, J=2.4 Hz, 1H), 7.35 (d, J=2.0 Hz, 1H), 7.26-7.18 (m, 1H), 2.42-2.38 (m, 2H), 2.22-2.10 (m, 4H); LC-MS: m/z 407.1 (M-H)". Example-VII (Method-A): N-(5'-((2.4-difluorophenyl)sulfonamidoV2'-oxospiro [cyclobutane-1.3'-indolin]-7'-yl)-l-methylpiperidine-4-carboxamide fCompound-43) 0 NH COOH T Compound-15 Compound-43 To a solution of N-(7'-amino-2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yl)-2,4- difluorobenzenesulfonamide (compound-15) (0.1 g, 0.26 mmol) in DMF (2 mL) were added l-methylpiperidine-4-carboxylic acid (0.074 g, 0.52 mmol), triethylamine (0.14 mL, 1.04 mmol) and PyBOP (0.27 g, 0.52 mmol). The mixture was stirred at RT for 16 h. The mixture was diluted with EtOAc (50 mL), washed with water (50 mL) and brine (50 mL), dried over sodium sulphate and concentrated under reduced pressure and column purified to afford the title compound as off white solid (0.01 g, 8%).^ NMR (400 MHz, DMSO-d6) 5 10.22 (bs, 1H), 9.81 (s, 1H), 9.19 (s, 1H), 7.84-7.79 (m, 1H), 7.53 (t, J=8.6 Hz, 1H), 7.27 (s, 1H), 7.24-7.20 (m, 1H), 7.03(d, J=1.5 Hz,lH), 3.17-3.16 (m, 1H), 2.88-2.85 (m, 2H), 2.41-2.35 (m, 2H), 2.29-1.91 (m, 9H), 1.79-1.76 (m, 2H), 1.68-1.60 (m, 2H): LC-MS: m/z 505.2 (M+H)+. The below compounds were prepared by procedure similar to the one described in Example-VII (method-A) with appropriate variations in reactants, quantities of reagents and reaction conditions. The physiochemical characteristics of the compounds are also summarized. (Method-B): 2.4-difluoro-N-(7'-(4-methylpiperazine-l-carbonvl)-2'-ox6spiro [cyclobutane-1.3'-indolin]-5'-yl)benzenesulfonamide (Compound-47) To a solution of 5'-((2,4-difluorophenyl)sulfonamido)-2'-oxospiro[cyclo- butane-1.3'-indoline]-7'-carboxylic acid (compound-42) (0.1 g, 0.24 mmol) inDMF (3 mL) were added 1-methylpiperazine (0.032 mL, 0.29 mmol), HOBt (0.05 g, 0.36 mmol), EDC.HC1 (0,07 g, 0.36 mmol) and diisopropylethylamine (0.13 mL, 0.72 mmol. The mixture was stirred at RT for 16 h, diluted with EtOAc (50 mL), washed with water (50 mL) and brine (50 mL), dried over sodium sulphate and concentrated under reduced pressure and column purified to afford the title compound as white solid (0.03 g, 25%); 'H NMR (400 MHz, DMSO-d6): 5 10.37 (s, 1H), 10.32 (s, 1H), 7.80-7.78 (m, 1H), 7.57-7.52 (m, 1H), 7.32 (s, 1H), 7.23 (t, J=7.3 Hz, 1H), 6.67 (d, J=1.5 Hz, 1H), 3.60-3.54 (m, 2H), 3.15-3.04 (m, 2H), 2.44-2.30 (m, 4H), 2.17 (s, 3H), 2.20-2.12 (m, 6H); LC-MS: m/z 491.1 (M+H)+. ' The below compounds were prepared by procedure similar to the one described in Example-VII (method-B) with appropriate variations in reactants, quantities of reagents and reaction conditions. The physiochemical characteristics of the compounds are also summarized. Exam pie-VIH: 4-Fluoro-N-(7'-(morpholine-4-carbonvl)-2'-oxospiro[cyclobutarie- 1.3'-indo]in]-5'-yl):2-morpholinoben2enesulfonamide: (Compound-61) To a solution of N-(7'-bromo-2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yl)-2,4- difluorobenzenesulfonamlde (intermediate-1) (0.1 g, 0.23 mmol) in toluene (10 mL) were added xantphos (0.013g, 0.023 mmol), palladium(ll)acetate (0.01 g, 0.046 mmol), potassium phosphate (0.15 g, 0.69 mmol) and morpholine (0.024 mL, 0.28 mmol). The reaction mixture was purged with carbon monoxide gas for 10 min and then heated to 110 °C for 6 h under carbon monoxide atmosphere. The mixture was diluted with EtOAc (50 mL), washed with water (50 mL) and brine (50 mL), dried over sodium sulphate and concentrated under reduced pressure and purified by preparative HPLC to afford the title compound as brown solid (0.03 g, 27%). 'H NMR (400 MHz, DMSO-dfi): 5 10.30 (s, 1H), 9.58 (s, III), 7.94-7.91 (m, 1H), 7.29 (dd, J=2.6 Hz & 10.8 Hz, 1H), 7.20 (d, J=2.1 Hz, 1H), 7.12-7.08 (m, 1H), 6.67 (d, .7=2.1 Hz, 1H), 3.82-3.80 (m, 4H), 3.65-3.37 (m, 6H), 3.10-3.03 (m, 2H), 2.90-2.88 (m, 4H), 2.42-2.36 (m, 2H), 2.20-2.07 (m, 4H); LC-MS: m/z 545.2 (M+H)+. Example-IX: 2.4-Difluoro-N-(2'-oxo-7'-(pyridin-4-ylamino)spiro[cyclobutane-1.3'- indolin]-5'-yl)benzenesulfonamide (Compound-62) To a solution of N-(7'-amino-2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yl)-2,4- difluorobenzenesulfonamide (compound-1.5) (0.1 g, 0.26 mmol) in HC1 in 1,4- dioxane (10 mL) was added 4-chloropyridine (0.025 mL, 0.26 mmol) in a sealed tube. The mixture was heated to 110 °C for 16 h. The mixture was diluted with DCM (50 mL), washed with aqueous sodium bicarbonate (50 m,L) and brine (50 mL), dried over sodium sulphate, concentrated under reduced pressure and purified by preparative HPLC to afford the title compound as white solid (0.025 g, 21%). 'H NMR (400 MHz, DMSO-&): 5 10.38 (bs, 1H), 10.01 (s, 1H), 8.13 (d, .7=6.3 Hz, 2H), 8.08 (s, 1H), 7.85-7.79 (m, 1H), 7.61-7.55 (m, 1H), 7.29-7.25 (m, 1H), 7.10 (d, J=1.5 Hz, 1H), 6.77 (d, J=1.5 Hz, 1H), 6.47 (d, J=5.8 Hz, 2H), 2.45-2.33 (m, 2H), 2.20- 2.08 (m, 4H); LC-MS: m/z 457.1 (M+H)+. Example-X: N-(5'-((2.4-difluorophenyl)sulfonamidoV2'-oxospiro[cyclobutane-1.3'- indolin]-7'-yl)acetamide (Compound-63) A solution of N-(7'-amino-2'-oxospiro[cyclobutane-1,3'-indolin]-5'-yl)-2,4- difluorobenzenesulfonamide (compound-15) (0.15 g, 0.39 mmol) in acetic anhydride (1 mL) was stirred at RT for 48 h. The mixture was poured into ice water and the solid formed was filtered off. The product was washed with water and dried under reduced pressure to afford the title compound as white solid (0.08 g, 48 %). 'H NMR (400 MHz, DMSO-d6): 5 10.35 (s, 1H), 9.78 (s, 1H), 9.32 (s, 1H), 7.85-7.78 (m, 1H), 7.56-7.50 (m, 1H), 7.25-7.20 (m, 1H), 7.14 (s, 1H), 7.05 (d, .7=1.5 Hz, 1H), 2.43-2.33 (m, 2H), 2.17-2.00 (m, 4H), 1.98 (s, 3H); LC-MS: m/z 422.1 (M+H)+. Example-XI: 5'-((2-methoxyphenyl)sulfonamido)-2'-oxo-N-(piperidin-4-ynspiro [cyclobutane-1.3'-indoline]-7'-carboxamide (Compound-64) Step-(i): Methyl 5'-((2-methoxypheny0sulfonamido)-2'-oxospiro[cyclo- butane-1.3'-indoline]-7'-carboxylate (64.11 The process of this step was adopted from step-(i) of Example-VI. 'H NMR (400 MHz, DMSO-^0: 5 10.05 (s, 1H), 9.90 (s, 1H), 7.72-7.69 (m, 1H), 7.55-7.48 (m, 1H), 7.42 (s, 1H), 7.40 (s, 1H), 7.16 (d, J=8.4 Hz, 1H), 7.01-6.98 (m, 1H), 3.90 (s, 3H), 3.79 (s, 3H), 2.39-2.32 (m, 2H), 2.19-2.11 (m, 4H); LC-MS: m/z 417.0 (M+H)+. Step-(ii): 5'-((2-Methoxyphenyl)sulfonamido)-2'-oxospiro[cyclobutane-1.3'- indoline]-7'-carboxylicacid (64.21 The process of this step was adopted from step-(ii) of Example-VI. 1HNMR (400 MHz, DMSO-rf«): 5 12.02 (bs, 1H), 9.86 (s, 1H), 9.68 (s, 1H), 7.71-7.69 (m, 1H), 7.52-7.50 (m, 1H), 7.46 (d, J=1.9 Hz, 1H), 7.38 (d, J=2.5 Hz, 1H), 7.16 (d, J-8.3 Hz, 1H), 7.02-6.98 (m, 1H), 3.90 (s, 3H), 2.45-2.32 (m, 2H), 2.25-2.16 (m, 4H); LC-MS: m/z 403.0 (M+H)+. Step-(iii): tert-Butyl 4-f5'-ff2-memoxvphenyl)sulfonamido>2'-oxospiro [cyclobutane-13'-indoline]-7'-carboxamido')piperidine-l-carboxylate (64.3s) The process of this step was adopted from Example-VII (Method-B). lH NMR (400 MHz, DMSO-rfs): 5 9.76 (s, 1H), 9.68 (s, 1H), 8.32 (d, J=7.9 Hz, 1H), 7.64 (dd, J=\ ,5 Hz & 7.8 Hz, 1H), 7.59-7.54 (m, 1H), 7.32 (d, J=2.0 Hz, 1H), 7.21 (d, J=8.3 Hz, 1H), 7.13 (d, J=1.5 Hz, 1H), 6.99 (t, .7=7.6 Hz, 1H), 3.92 (s, 3H), 3.87- 3.85 (m, 1H), 2.82-2.78 (m, 2H), 2.39-2.33 (m, 2H), 2.19-2.14 (m, 2H), 2.08-1.94 (m, 4H), 1.78-1.76 (m, 2H), 1.41 (s, 9H), 1.39-1.27 (m, 2H); LC-MS: m/z 583.2 (M- H)-. Step-(ivV 5'-((2-Methoxyphenyflsulfonamido)-2'-oxo-N-(piperidin-4-yl)spiro [cyciobutane-1.3'-indoUne]-7'-carboxamide (compound-64) To a solution of tert-butyl 4-(5'-((2-methoxyphenyl)sulfonamido)-2'-oxo- spiro[cyclobutane-1,3'-indoline]-7'-carboxamido)piperidine-l-carboxylate (0.08 g, 0.136 mmol) in DCM (2 mL) wasadded TFA (0.05 mL, 0.68 mmol) at RT for 3 h. The mixture was diluted with DCM and washed with saturated NaHC03. The organic layer was dried over sodium sulphate, concentrated under reduced pressure and washed with diethyl ether to afford the title compound as pale yellow solid (0.03 g, 45%). 'H NMR (400 MHz, DMSO-^): 5 8.34 (d, J=7.3 Hz, 1H), 7.64 (dd, J=1.4 Hz & 7.8 Hz, 1H), 7.58-7.54 (m, 1H), 7.34 (d, J=2.0 Hz, 1H), 7.20 (d, J=8.3 Hz, 1H), 7.11 (d, J=2.0 Hz, 1H), 6.98 (t, J=7.9 Hz, 1H), 3.92 (s, 3H), 3.79-3.72 (m, 1H), 2.95 (d, J=12.2 Hz, 2H), 2.67-2.47 (m, 3H), 2.50-2.48 (m, 2H), 2.40-1.94 (m, 4H)1.72 (d, J=9.8 Hz, 2H), 1.44-1.24 (m, 2H); LC-MS: m/z 485.2 (M+H)+. The below compounds were prepared by procedure similar to the one described in Example-XI with appropriate variations in reactants, quantities of reagents and reaction conditions. The physiochemical characteristics of the compounds are also summarized. * Isomer-1 and 2 were separated by using Chiral HPLC under below conditioi Column: Chiralpak-IA(250*4.6*5.0u) Mobile phase-A: 0.1% DEA in n-Hexane; Mobile phase-B:Ethanol Isocratic: 70:30(A:B); Flow rate: 1.0 ml/min Column temp: Ambient Diluent: Mobile phase Exarnple-XH: 2.4-Difluoro-N-(7'-(hydroxymethyn-2'-oxospiro[cyclobutane-13'- indolin]-5'-yl)benzenesulfonamide (Compound-69^ To a cooled solution of methyl 5'-((2,4-difluorophenyl)sulfonamido)-2'-oxo- spiro[cyclobutane-1,3'-indoline]-7'-carbdxylate (compound-41) (0.15 g, 0.35 mmol) in THF (5 mL) was added Red-Al 60 % in toluene (0.21 g, 1.05 mmol). The mixture was stirred at RT for 16 h. The reaction mixture was then quenched with rochelle salt, extracted with EtOAc (50 mL) and washed with water (50 mL) and brine (50 mL), dried over sodium sulphate, concentrated under reduced pressure and purified by preparative TLC to afford the title compound as off white solid (0.08 g, 57 %).'H NMR (400 MHz, DMSO-2.2 Hz, 1H), 6.60 (d, J=2.0 Hz, 1H), 3.09-3.06 (m, 2H), 2.67-2.56 (m, 2H), 2.42-2.32 (m, 4H), 2.19-2.03 (m, 4H), 1.70- 1.67 (m, 2H), 1.35-1.23 (m, 3H), 1.13-1,01 (m, 2H); LC-MS: m/z 476.2 (M+H)+. Step-iv: 2.4-Difluoro-N-(7'-r2-(l-methy]piperidin-4-yl)ethyl)-2'-oXospiro [cyclo butane-1.3'-indolin]-5'-yl)benzenesulfonamide (116) The process of this step was adopted from Example-XX (compound-89) alkylation. *HNMR (400 MHz, DMSO-ek): 5 10.27 (s, 1H), 10.10 (bs, 1H), 7.80- 7.74 (m, 1H), 7.55-7.50 (m, 1H), 7.23-7.18 (m, 1H), 7.05 (d, J=2.0 Hz, 1H), 6.62 (d, .7=1.9 Hz, 1H), 2.76-2.73 (m, 2H), 2.42-2.32 (m, 4H), 2.16 (s, 3H), 2.14-2.04 (m, 4H), 1.85-1.78 (m, 2H), 1.63-1.57 (m, 2H), 1.24-1.22 (m, 3H), 1.18-1.04 (m, 2H); LC-MS: m/z 490.2 (M+H)+. Step-i: N-(7'-(1.2-dihydroxy-l-phenylethyl)-2'-oxospiro[cyclobutane-1.3'- indolin]-5'-ylV2-methoxybenzenesulfonarnide (117.1) To a solution of 2-methoxy-N-(2'-oxo-7,-(l-phenylvinyl)spiro[cyclobutane- 1,3'-indolin]-5'-yl)benzenesulfonamide (0.6 g, 1.30 mmol) in acetone (6 mL) were added NMO (0.27 mL, 2.6 mmol) and osmium tetroxide 4 % in water (0.03 mL) followed by stirring at RT for 16 h. The reaction mixture was quenched with aqueous sodium metabisulfite and extracted with EtOAc. The organic layer was dried over sodium sulphate, concentrated under reduced pressure and purified by combi flash to afford the title compound as off white solid (0.48 g, 75%). Step-ii: N-(7'-benzoyl-2'-oxospiro[cyclobutane-1.3'-indolin]-5'-ylV2- methoxybenzenesulfonamide (117) To a solution of N-(7'-(l,2-dihydroxy-l-phenylethyl)-2'-oxospiro[cyclo- butane-1,3'-indolin]-5'-yl)-2-methoxybenzenesulfonamide (0.48 g, 0.97 mmol) in mixture of THF (8 mL) and water (1 mL) was added sodium meta periodate (2.06 g, 9.70 mmol) followed by stirring at 80 °C for 2 h. The mixture was diluted with water and extracted with EtOAc. The organic layer was dried over sodium sulphate, concentrated under reduced pressure and purified by combi flash to afford the title compound as white solid (0.24 g, 55 %). Example-XXXI: N-(7'-(hydroxy(phenyl)methyl)-2'-oxospiro[cyclobutane-1.3'- indolin]-5'-yl)-2-methoxybenzenesulfonamide Compound-118 To a cold solution of N-(7'-benzoyl-2'-oxospiro[cyclobutane-1,3'-indolin]-5'- yl)-2-methoxybenzenesulfonamide (0.1 g, 0.216 mmol) in MeOH (4 mL) was added sodium borohydride (0.025 g, 0.65 mmol) followed by stirring at RT for 16 h. The mixture was concentrated under reduced pressure, diluted with water and extracted with EtOAc (50 ml x 2). The organic layer was dried over sodium sulphate, concentrated under reduced pressure and purified by combi flash to afford the title icompound as white solid (0.03 g, 30 %); 'H NMR (400 MHz, DMSO-J6): 5 10.15 (s, 1H), 9.57 (s, 1H), 7.62 (dd, J=1.5 Hz, 7.9 Hz, 1H), 7.55-7.51 (m, 1H), 7.26-7.21 (m, 5H), 7.19-7.09 (m, 2H), 7.00-6.94 (2H), 5.76 (d, J=3.4 Hz, 1H), 5.69 (d, .7=3.4 Hz, 1H), 3.83 (s, 3H), 2.39-2.32 (m, 2H), 2.18-2.00 (m, 4H); LCMS: m/z 463.1 (M-H)". lExample-XXXII: N-(7'-( 1 -hydroxy-1 -phenylethyl)-2'-oxospiro[cyclobutane-1.3'- indolin]-5'-ylV2-methoxybenzenesulfonamide (Compound-120) To a stirring suspension of ZnCl2 (0.0003 g, 0.022 mmol) in THF was added imethyl magnesium bromide (0.47 mL, 0.66 mmol) followed by stirring at RT for 1 h. The mixture was cooled to 0 °C and N-(7'-benzoyl-2'-oxospiro [cyclobutane-1,3'- indolin]-5'-yl)-2-methoxy benzenesulfonamide (0.1 g, 0.22) in THF was added followed by stirring at 0 °C for 2 h. The reaction mixture was quenched with saturated ammonium chloride and extracted with EtOAc. The organic layer was dried lover sodium sulphate, concentrated under reduced pressure and purified by combi flash to afford the title compound as white solid (0.02 g, 20 %). 'H NMR (400 MHz, DMSO-J6): 5 9.57 (s, 1H), 8.69 (s, 1H), 7.64 (d, J=7.9 Hz, 1H), 7.58 (t, J=6.8 Hz, 1H), 7.22 (d, J=6.9 Hz, 2H), 7.17-7.15 (m, 5H), 7.00 (t, J=7:8Hz, 1H), 6.83 (d, J=1.9 Hz, 1H), 6.09 (s, 1H), 3.88 (s, 3H), 2.37-2.31 (m, 2H), 2.15-2.05 (m, 4H), 1.64 (s, i3H); LCMS: m/z 477.1 (M-H)". Example-XXXHI: i-(7'-Cyclopropyl-2'-oxospiro[cyclobutane-K3'-indolin]-5'-ylV3- (2-methoxyphenyl)urea (Compound-121.) 5 - A mixture of intermediate-8 (0.1 g, 0.43 mmol) and pyridine (0.113 g, 1.31 mmol) in DCM (10 mL) was cooled to 0 °C. l-Isocyanato-2-methoxybenzene (0.0065 g, 0.43 mmol) was then added. The mixture was gradually warmed to RT 5and stirred for 2 h. The solid formed was filtered, washed with ether and hexanes to get the title compound (0.07 g, 42 %). 1H-NMR (400MHz DMSO-^): 10.18 (s, 1H), 9.14 9s, 1H), 8.13-8.10 (m, 2H), 7.53 9s, 1H), 7.01 (d, 1H), 6.94-6.86 (m, 2H), 6.63 (s, 1H), 3.87 (s, 3H), 2.50-2.41 (m, 4H), 2.26-2.14 (m, 4H), 1.93-1.92 (m, 1H), 0.92 (d, 2H), 0.59 (d, 2H). LC-MS: m/z 378.1 (M+H)+. 10 Example-XXXIV: 2-Methoxy-N-(2'-oxo-7'-( 1 -(pyridin-3 -yl)ethyl)spiro [cyclo- butane-1,3'-indolin]-5'-yl)benzenesulfonamide (Compound 122) Step-i: 5'-Nitro-7'-ri-(pyridin-3-vnvinyl)spiro[cyclobutane-1.3'-indolin]-2'- 15one To a solution of 5'-nitro-7'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro- [cyclobutane-1,3'-indolin]-2'-one (intermediate-9) (0.5 g, 1.45 mmol) in 1,4-dioxane (10 mL) and H20 (3 mL) in a sealed tube were added l-(pyridin-3-yl)vinyl trifluoro methanesulfonate (intermediate-10) (0.73 g, 2.90 mmol) and sodium carbonate (0.38 20g, 3.62 mmol). The mixture was degassed with nitrogen purging for 20 min. Then Pd (PPh3)4 (0.17 g, 0.145 mmol) was added followed by heating at 100 °C for 16 h. The mixture was concentrated under reduced pressure and the residue was diluted with EtOAc (100 ml), washed with water (100 mL) and brine (100 mL), dried over sodium sulphate, concentrated under reduced pressure and purified by combi flash to 25afford the title compound as yellow solid (0.4 g). 'H NMR (400 MHz, DMSO-tf6): 5 10.72 (s, 1H), 8.57 (d, J=2.5 Hz, 1.H), 8.54 (d, .7=1.5 Hz, 1H), 8.53 (dTJ=1.0 Hz, 1H), 7.90 (d, J= 2.4 Hz, 1H), 7.68-7.53 (m, 1H), 7.40-7.36 (m, 1H), 6.10 (s, 1H), 5.56 (s, 1H), 2.48-2.41 (m, 4H), 2.28-2.22 (m, 2H); LCMS: m/z 322.2 (M+H). Step-ii: 5'-Amino-7'-(l-rpyridin-3-ynethynspiro[cyclobutane-1.3'-indolin]-2'- one i To a solution of 5'-nitro-7'-(l-(pyridin-3-yl)vinyl)spiro[cyclobutane-1,3'- indolin]-2'-one (0.4 g, 1.51 mmol) in MeOH (5 mL) was added Palladium hydroxide (0.2 g) followed by stirring under H2 bladder pressure at RT for 6 h. The mixture was filtered through celite bed and washed with EtOAc. The organic layer was concentrated under reduced pressure and purified by combi flash to afford the title ^compound as white solid (0.18 g). 'H NMR (400 MHz, DMSO-d«): 5 10.01 (s, 1H), 8.52 (d, J=2.4 Hz,.lH), 8.38 (dd, J-1.4 Hz, 4.9 Hz, 1H), 7.64 (d, J=7.9 Hz, 1H), 7.32-7.29 (m, 1H), 6.69 (d, J=2.0 Hz, 1H), 6.32 (d, J = 2.0 Hz, 1H), 4.69 (bs, 2H), 4.23 (q, J=7.4 Hz, 1H), 2.44-2.33 (m, 2H), 2.20-2.08 (m, 4H), 1.49 (d, J=7.4 Hz, 3H); LCMS: m/z 294.2 (M+H). Step-iii: Synthesis of 2-methoxy-N-(2'-oxo-7'-(l-(pyridin-3-yl)ethyl)spiro- [cyclobutane-1.3'-indolin]-5'-yDbenzenesulfonamide To an ice cooled solution of 5'-amino-7'-(l-(pyridin-3-yl)ethyl)spiro[cyclo- butane-1,3'-indolin]-2'-one (0.15 g, 0.51 mmol) in DCM (6 mL) were added pyridine (0.2 mL, 2.55 mmol) and 2-methoxy benzenesulfonyl chloride (0.13 g, 0.61 mmol) folloed by stirring at RT for 3 h. The mixture was diluted with DCM (100 mL) and washed with water (100 mL) and brine (100 mL), dried over sodium sulphate and concentrated under reduced pressure and purified by preparative HPLC to afford the title compound as white solid (0.05 g, 21 %). 'H NMR (400 MHz, DMSO-rf6): 8 10.33 (s, 1H), 9.55 (s, 1H), 8.40-8.37 (m, 2H), 7.61 (dd, 7=1.5 Hz, 7.8 Hz, 1H), 7.56- 17.52 (m, 1H), 7.35-7.32 (m, 1H), 7.29-7.26 (m, 1H), 7.13-7.11 (m, 2H), 6.97 (t, J=7.4 Hz, 1H), 6.74 (d, J=1.9 Hz, 1H), 4.20 (q, J=6.9 Hz, 1H), 3.84 (s, 3H), 2-40-2.32 (m, 2H), 2.20-2.05 (m, 4H), 1.38 (d, J=6.8 Hz, 3H); LCMS: m/z 464.2 (M+H)+. Exatnple-XXXV: 2-Methoxy-N-(2'-oxo-7'-n-(pyridin-2-yl)ethyl)spiro [cvclobutane- ' iL3'-indolin]-5'-yl)benzenesulfonamide (Compound 123) Step-i: 5'-Nitro-7'-ri-fpyridin-2-ynvinvnspiro[cyclobutane-13'-indolin]-2'- one The process of this step was adopted from Example-XXXIV of step-i. 'H NMR (400 MHz, DMSO-d6): 5 10.73 (s, 1H), 8.53 (d, 7=4.9 Hz, 1H), 8.47 (d, 7=2.5 Hz, 1H), 7.90 (d, .7=2.0 Hz, 1H), 7.83-7.79 (m, 1H), 7.53 (d, J = 7.9 Hz, 1H), 7.35-7.32 (m, 1H), 6.43 (s, 1H), 5.65 (s, 1H), 2.46-2.41 (m, 2H), 2.28-2.19 (m, 4H); LCMS:m/z 322.1 (M+H)+. Step-ii: 5'-Amino-7'-ri-(pyridin-2-vnethyl)spiro[cyclobutane-1.3'-indolin]-2'- one The process of this step was adopted from Example-XXXIV of step-ii. 'HNMR (400 MHz, DMSO-J6): 5 10.0 (s, 1H), 8.57 (d, J=3.9 Hz, 1H), 7.70-7.66 (m, 1H), 7.29 (d, 7=7.8 Hz, 1H), 7.21-7.18 (m, 1H), 6.65 (d, 7=2.4 Hz, 1H), 6.28 (d, J= 1.9 Hz, 1H), 4.64 (bs, 2H), 4.31 (q, 7=6.8 Hz, 1H), 2.42-2.33 (m, 2H), 2.17-2.06 (m, 4H), 1.50 (d, J=7.4 Hz, 3H); LCMS: m/z 294.0 (M+H)+. Step-iii: 2-Methoxy-N-(2'-oxo-7'-(l-(pyridin-2-yl)ethyl)spiro[cyclobutane- 1.3'-indolin]-5'-ynbenzenesulfonamide The process of this step was adopted from Example- XXXIV of step-iii. 'H NMR (400 MHz, DMSO-J6): 5 10.35 (s, 1H), 9.48 (s, 1H), 8.50 (d, .7=3.9 Hz, 1H), 7.68-7.64 (m, 1H), 7.57-7.54 (m, 1H), 7.53-7.48 (m, 1H), 7.22-7.19 (m, 1H), 7.14-7.08 (m, 3H), 6.93 (t, 7=7.8 Hz, 1H), 6.73 (d, .7=2.0 Hz, 1H), 4.28 (q, .7=6.9 Hz, 1H), 3.83 (s, 3H), 2.40-2.33 (m, 2H), 2.20-2.05 (m, 4H), 1.38 (d, 7=6.8 Hz, 3H); LCMS: m/z 464.2 (M+H)+. Example-XXXVI: 2-Methoxy-N-(2'-oxo-7'-(pyridin-2-yloxy)spiro[cyclobutane-1.3'- indolinl-5'-yl)benzenesulfonamide (Compound 124) Step-i: 7'-Hydroxy-5'-nitrospiro[cyclobutane-1.3'-indolin]-2'-one To a cold solution of 5'-nitro-7'-(4,4,5,5-teframethyl-1,3,2-dioxaborolan-2-yl)- spiro[cyclobutane-1,3'-indolin]-2'-one (0.45 g, 1.31 mmol) in THF (10 mL) was added hydrogen peroxide 30 % in water (2.5 mL) followed by stirring at RT for 6 h. The mixture was diluted with water and extracted with EtOAc. The organic layer was dried over sodium sulphate and concentrated under reduced pressure. The obtained solid was washed with diethyl ether to afford the title compound as yellow solid (0.35 g). 'HNMR (400 MHz, DMSO-d&): 5 10.78 (s, 1H), 10.54 (s, 1H), 8.01 (d, 7=2.0 Hz, 1H), 7.61 (d, 7=1.9 Hz, 1H), 2.43-2.39 (m, 4H), 2.25-2.16 (m, 2H). Step-ii: 5'-Nitro-7Wpyridin-2-yloxy)spiro[cvclobutanc-1.3'-indolin]-2'-one To a solution of 7'-hydroxy-5'-nitrospiro[cyclobutane-1,3'-indolin]-2'-one (0.18 g, 0.72 mmol) in DMF (2 mL) was added potassium carbonate (0.3 g, 2.16 mmol) and 2-fluoro pyridine (0.14 g, 1.44 mmol) followed by heating to 150 °C for 16 h. The mixture was diluted with EtOAc and washed with water. The organic layer was dried over sodium sulphate, concentrated under reduced pressure and purified by combi flash to afford the title compound as yellow solid (0.11 g, 50 %). 'HNMR (400 MHz, DMSO-rf6): 5 11.20 (s, 1H), 8.40 (d, .7=1.9 Hz, 1H), 8.11 (dd, J=1.5 Hz, 4.9 Hz, 1H), 7.97 (d, J=1.9 Hz, 1H), 7.92-7.88 (m, 1H), 7.18-7.14 (m, 2H), 2.47-2.42 (m, 4H), 2.26-1.98 (m, 2H); LCMS: m/z 312.1 (M+H)+. Step-iii: 5'-Amino-7'-(pyridin-2-yloxy)spiro[cyclobutane-L3'-indolin]-2'-one: The process of this step was adopted from step-e of Intermediate-1. 'H NMR (400 MHz, DMSO-rf6): 5 9.95 (s, 1H), 8.11 (dd, 7=1.4 Hz, 4.9 Hz, 1H), 7.82-7.78 (m, 1H), 7.09-7.06 (m, 1H), 6.94 (d, .7=8.3 Hz, 1H), 6.72 (d, .7=1.9 Hz, 1H), 6.14 (d, J=2.0, 1H), 4.89-4.88 (bs, 2H), 2.46-2.40 (m, 2H), 2.33-2.14 (m, 4H); LCMS: m/z 282.2 (M+H)+. Step-iv: 2-Methoxy-N-(2'-oxo-7'-(pvridin-2-yloxy)spiro[cyclobutane-1.3'- indolin]-5'-yl)benzenesulfonamide The process of this step was adopted from step-f of Intermediate-1. 'H NMR (400 MHz, DMSO-ck): 5 10.32 (s, 1H), 9.75 (s, 1H), 8.06 (d, 7= 4.4 Hz, 1H), 7.81 (t, J=8.4 Hz, 1H), 7.69 (d, 7=7.8 Hz, 1H), 7.56 (t, 7=8.3 Hz, 1H), 7.17-7.09 (m, 3H), 7.01 (t, 7=7.3 Hz, 1H), 6.92 (d, J=8.3 Hz, 1H), 6.63 (s, 1H), 3.85 (s, 3H), 2.42-2.32 (m, 2H), 2.19-2.07 (m, 4H); LCMS: m/z 452.2 (M+H)+. Example-XXXVH: N-(7'-ffluorofphenyl)memyl)-2'-oxospiro[cyclobutane-1.3'- indolin]-5'-yl)-2-methoxybenzenesulfonaimide (Compound .125) To a cold solution of N-(7'-(hydroxy(phenyl)methyl)-2'- oxospiro[cyclobutane-1,3'-indolin]-5'-yl)-2-methoxybenzenesulfonamide (0.09 g, 0.19 mmol) in DCM (4 mL) was added DAST (0.025 mL, 0.19 mmol) followed by stirring at RT for 30 min. The mixture was diluted with DCM and washed with saturated NaHCO3. The organic layer was dried over sodium sulphate, concentrated and purified by combi flash to afford the title compound as brick red solid (0.03 g, 33 %). 1H NMR (400 MHz, DMSO-d6): δ 10.48 (s, 1H), 9.66 (s, 1H), 7.60 (d, 7= 7.8 Hz, 1H), 7.54 (t, 7=7.3 Hz, 1H), 7.38-7.37 (m, 3H), 7.26 (s, 1H), 7.18 (d, 7=6.4 Hz, 2H), 7.10 (d, 7=8.3 Hz, 1H), 6.97 (t, 7=7.4 Hz, 1H), 6.80 (s, 1H), 6.69-6.58 (m, 1H), . 3.79 (s, 3H), 2.40-2.32 (m, 2H), 2.20-2.09 (m, 4H); LCMS: m/z 467.2 (M+H)+. Example-XXXVIII: 2.4-Difluoro-N-C2'-oxo-7'-ri-phenylethyl)spiro[cyclobutane- l.,3'-indolin]-5'-yl)benzenesulfonamide (Compound 126) Step-i: 2.4-Difluoro-N-f2'-oxo-7'-(l-phenyIvinyl)spiro[cyclobutane-1.3'- indolin]-5'-yl)benzenesulfonamide The process of this step was adopted from Example-I. 'H NMR (400 MHz, DMSO-J5): 5 10.22 (s, 1H), 9.94 (s, 1H), 7.76-7.70 (m, 1H), 7.53-7.48 (m, 1H), 7.31- 7.29 (m, 4H), 7.24-7.20 (m, 1H), 7.12-7.08 (m, 2H), 6.51 (d, J-2.0 Hz, 1H), 5.77 (s, 1H), 5.20 (s, 1H), 2.43-2.32 (m, 2H), 2.21-2.12 (m, 4H); LC-MS: m/z 467.1 (M+H)+. Step-ii: 2.4-Difluoro-N-(2'-oxo-7'-(l-phenylethyl)spiro[cyclobutane-1.3'- indolin]-5'-yl)benzenesulfonamide The process of this step was adopted from Example-XXVTfl. 'H NMR (400 MHz, DMSO-d6): 5 10.37 (s, 1H), 10.16 (s, 1H), 7.72-7.66 (m, 1H), 7.52-7.47 (m, 1H), 7.26-7.19 (m, 4H), 7.17-7.07 (m3 3H), 6.66 (d, J=1.9 Hz, 1H), 4.20 (q, J=6.8 Hz, 1H), 2.40-2.33 (m, 2H), 2.20-2.07 (m, 4H), 1.35 (d, J=7.4 Hz, 3H); LC-MS: m/z 469.1 (M+H)+. Biological Data In-Vitro biochemical data of spiro[cyclobutane-1,3'-indolin]-2'-one derivatives in time-resolved fluorescence resonance energy transfer (TR-FRET) assay. The Bet bromodomain TR-FRET assay has been used to identify compounds that bind to Bet BRD4 bromodomain and prevent its interaction with acetylated histone peptides (Chung, C. et al., J. Med. Chem., 54, 3827-3838, 2011). In the assay, optimized concentration of in-house BetBRD4 bromo- domain protein and 300 nM of acetyl histone peptide substrate were diluted in assay buffer (50 mM HEPES, pH: 7.5, 50 raM NaCI, 500 uM CHAPS) and were added to the positive control and test control wells in a 384 well plate. Substrate control wells have 300 nM of acetyl histone peptide substrate diluted in assay buffer. Buffer blank wells were added with assay buffer. The reaction mixture was allowed for incubation at RT for 30 min. Stock solutions of test compounds at 20 mM DMSO were prepared. Compounds were serially diluted and added to the test wells in 384-well polypropylene plates. The reaction mixture was further incubated for 30 min at RT on a plate shaker. 2 nM of Europium labeled streptavidin and 10 nM of XL-665 labeled antibody diluted in detection buffer (50 mM HEPES, pH: 7.5, 50 mM NaCl, 500 uM CHAPS and 800 mM KF) were added to all the wells excluding the buffer blank wells. The reaction plate was incubated for additional 30 min at RT on plate shaker. The plate was read in Perkin Elmer WALLAC 1420 Multilabel Counter Victor 3 (Ex: 340 nm Em: 615 and 665 nm). The amount of displacement of the peptide was measured as ratio of specific 665 nm energy transfer signal to 615 nm signals. The IC50 of the compounds was determined by fitting the dose response data to sigmoid curve fitting equation using Graph Pad Prism software V5. The compounds were screened in the above mentioned assay and the results (IC50) are summarized in the table below. The IC50 values of the compounds are set forth in below Table wherein "A" refers to an IC50 value of less than 600 nM, "B" refers to IC50 value in range of 600.01 to 1000 nM and "C" refers to IC50 value of greater than 1000 nM. Claims 1. A compound of formula (I) wherein Cy is a 4-12 membered monocyclic or bicyclic ring containing 0-4 hetero- atoms independently selected form N, O or S; L is a linker selected from -N(R3a)S(O)2-, -S(O)2N(R3b)-, -C(R3c)(OR3d)-, -N(R3e)C(O)-, -N(R3f)C(O)N(R3g)- or -N(R3h)C(O)CH(R3i)-; R3a, R3b,R3c,R3d,R3c, R3f, R3g, R3h and R3i are selected, independently, from hydrogen or C1-7 alkyl; R2 is halogen, C1-7 alkoxy, amino, cyano, oxo, -C(O)O-C1-7 alkyl, optionally substituted aryl or optionally substituted heterocyclyl, wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen or C1-7 alkoxy; in case wherein L is -S(O)2N(R3b)-, -C(R3c)(OR3d)-, -N(R3c)C(O)-, -N(R3f)C(O)N(R3g)- or -N(R3h)C(O)CH(R3i)-; then R1 is hydrogen, C1-7 alkyl, halogen, hydroxy C1-7 alkyl, C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl C 1.7 alkyl, optionally substituted aryl C2-7alkenyl, -NRaRb, -C(O)NRcRd, -C(O)ORe, -C(O)Rf,-C(ORg)-aryl, -C(ORh)(Ri)-aryl or -ORj; herein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, C1-7 alkyl or C1-7alkoxy; except that R1 is not hydrogen when L is -S(O)2NH- or -CH(OHT)-, and R, is not hydrogen or halogen when L is -NHC(O)CH(CH3)-; in case wherein L is -N(R3a)S(O)2- then R1 is-NRaRb3-C^NRcRd,-C(O)ORe, -C(O)Rf,-C(ORg)-aryl, -C(ORh)(Ri)-aryl or -ORj, -CH(CH3)-aryl, hydroxy C1-7 alkyl, aryl halo C1-7 alkyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl, optionally substituted aryl C2-7 alkenyl, optionally substituted 9-12 membered heterocyclic ring having 1-3 heteroatoms selected from N or O, pyridinyl having 1-2 substituents selected from halogen, hydroxy or C1-7alkoxy, 2-oxopiperidinyl, fluorophenyl C1-7 alkyl, 1-methylpiperidinyl (when at least one of R2 is halogen), piperidinyl (when at least two of R2 is C1-7alkoxy), phenyl C1-7 alkyl (when at least one of R2 is halogen and at least one another of R2 is C1-7alkoxy); wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, oxo, C1-7 alkyl or C1-7alkoxy; Ra, Rb, Rc and Rd are, independently, selected from hydrogen, C1-7 alkyl, C2-7 alkenyl, -C(O)-C1-7 alkyl, optionally substituted heterocyclyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl, optionally substituted aryl C1-7 alkyl, optionally substituted C3-10 cycloalkyl C1-7 alkyl, optionally substituted -C(O)heterocyclyl; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl, -C(O)-C1-7alkyl, -C(O)O-C1-7 alkyl, halogen, aryl C1-7alkyl, C1-7alkoxy, oxo or hydroxy C1-7 alkyl; Re, Rf, Rg, Rh, Ri and Rj are, independently, selected from hydrogen, C1-7 alkyl, optionally substituted aryl or optionally substituted heterocyclyl wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7alkyl or hydroxy C1-7alkyl; and 'm' is selected from 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof. 2. A compound according to claim I, wherein the compound is represented by formula (IA): wherein R1, R.2,Cy, L and 'm' are as defined in claim 1, or a pharmaceutically acceptable salt thereof. 3. A compound according to claim 1 or 2, wherein the compound is represented by formula (IB): wherein R1, R2, R3a, Cy and 'm' are as defined in claim 1, or a pharmaceutically acceptable salt thereof. 4. A compound according to claim 1 or 2, wherein the compound is represented by formula (IC): wherein R1, R2, R3f, R3g, Cy and 'm' are as defined in claim 1, or a pharmaceutically acceptable salt thereof. 5. A compound according to claim 1 or 2, wherein the compound is represented by formula (ID): wherein R1, R2, R3e, Cy and 'm' are are as defined in claim 1, or a pharmaceutically acceptable salt thereof. 6. A compound according to any of claims 1 to 5, wherein Cy is aromatic or non-aromatic cyclic ring with 5-10 ring atoms of which 0-4 are heteroatoms selected from a group consisting of N, O and S. 7. A compound according to claim 6, wherein Cy is phenyl, C3-10cycloallcyl or a 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from N or O. 8. A compound according to any of claims 1 to 7, wherein Cy is phenyl, C3-10 cycloalkyl or a 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from N or O; L is a linker selected from -N(R3a)S(O)2-, -N(R3c)C(O)- or -N(R3f)C(O)N(R3g)-; R3a, R3e,, R3f and R3g, are selected, independently, from hydrogen or C1-7 alkyl; R2 is halogen, C1-7alkoxy, cyano, -C(O)O-C1-7 alky 1 or a 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from N or O; in case wherein L is -N(R3e)C(O)- or -N(R3f)C(O)N(R3g)- then R1 is hydrogen, C1-7alkyl, halogen, hydroxy C1-7alkyl, C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl C1-7alkyl, optionally substituted aryl C1-7alkyl, optionally substituted aryl C2-7alkenyl, -NRaRb, -C(O)NRcRd, -C(O)ORe, -C(O)Rf,-C(ORs)-aryl, -C(ORh)(R,)-aryl or -ORj; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, C1-7 alkyl or C1-7alkoxy; in case wherein L is-N(R3a)S(O)2- then R1 is -NRaRb, -C(O)NRcRd) -C(O)ORe, -C(O)Rfj-C(ORg)-aryl; -C(ORh)(Ri)-aryl or -ORj, -CH(CH3)-aryl, hydroxy C1-7alkyl, aryl halo C1-7 alkyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl, optionally substituted aryl C2-7alkenyl, optionally substituted 9-12 membered heterocyclic ring having 1-3 heteroatoms selected from N or O, pyridinyl having 1-2 substituents selected from halogen, hydroxy or C1-7alkoxy, 2-oxopiperidinyl, fluorophenyl C1-7 alkyl, 1-methylpiperidinyl (when at least one of R2 is halogen), piperidinyl (when at least two of R2 is C1-7 alkoxy), phenyl C1-7 alkyl (when at least one of R2 is halogen and at least one another of R2 is C1-7 alkoxy); wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, oxo, C1-7 alkyl or C1-7 alkoxy; Ra, Rb, Rc and Rd are, independently, selected from hydrogen, C1-7 alkyl, C2-7 alkenyl, -C(O)-C1-7 alkyl, optionally substituted heterocyclyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted aryl, optionally substituted aryl C1-7 alkyl, optionally substituted C3-10 cycloalkyl C1-7 alkyl, optionally substituted -C(O)heterocyclyl; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl, -C(O)-C1-7 alkyl, -C(O)O-C1-7 alkyl, halogen, aryl C1-7 alkyl, C1-7 alkoxy, oxo or hydroxy C1-7 alkyl; Re, Rf, Rg, Rh, Ri and Rj are, independently, selected from hydrogen, C1-7 alkyl, optionally substituted aryl or optionally substituted heterocyclyl wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl or hydroxy C1-7 alkyl; and 'm' is selected from 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof. 9. A compound according to any of claims 1 to 8, wherein L is a linker selected from -NHS(O)2-, -NHC(O)- or-NHC(O)NH-. . 1.0. A compound according to any of claims 1 to 9, wherein L is -NHS(O)2-. 11. A compound according to any of claims 1-3 or 6-10, wherein Cy is phenyl, L is-NHS(O)2-, R2 is halogen or C1-7alkoxy, R1 is -NHRa, -C(O)NHRC, -C(O)ORe, -C(O)Rf,-C(OH)phenyl, -C(OH)( C1-7alkyl)phenyl or -ORj, -CH(CH3)phenyl, hydroxy C1-7alkyl, aryl halo C1-7 alkyl, optionally substituted heterocyclyl C1-7alkyl, optionally substituted phenyl, optionally substituted phenyl C2-7 alkenyl, optionally substituted 9-12 membered heterocyclic ring having 1-3 heteroatoms selected from N or O, pyridinyl having 1-2 substituents selected from halogen, hydroxy or C1-7 alkoxy, 2-oxopiperidinyl, fluorophenyl C1-7 alkyl, 1-methylpiperidinyl (when at least one of R2 is halogen), piperidinyl (when at least two of R2 is C1-7alkoxy), phenyl C1-7 alkyl (when at least one of R2 is halogen and at least one another of R2 is C1-7alkoxy); wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from halogen, hydroxy, oxo, C1-7 alkyl or C1-7 alkoxy; Ra and Rc are, independently, selected from hydrogen, C1-7 alkyl, C2-7 alkenyl, -C(O)-C1-7 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl C1-7 alkyl, optionally substituted C3-10 cycloalkyl C1-7 alkyl, optionally substituted -C(O)heterocyclyl; wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7 alkyl, -C(O)-C1-7 alkyl, -C(O)0-C1-7 alkyl, halogen, phenyl C1-7 alkyl, C1-7 alkoxy, oxo of hydroxy C1-7 alkyl; Re is hydrogen or C1-7 alkyl; Rf and Rj are independently optionally substituted phenyl or optionally substituted heterocyclyl wherein the optional substitution at each occurrence is, independently, selected from 1-3 substituents selected from C1-7alkyl or hydroxy C1-7 alkyl; wherein heterocyclyl at each occurrence is a 5-10 membered heterocyclic ring having 1-4 heteroatoms selected from O, N, or S; and 'm' is selected from 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof. 12. A compound according to any of claims 1-11, wherein Cy-(R2)m is selected from one of the following groups or tautomers thereof 13. A compound according to any of claims 1-12, wherein R1 is selected from one of the following groups or tautomers thereof 14. A compound according to any of claims 1-12, wherein R1 is -NHRa or -C(O)NHRc, wherein Ra, and Re are, independently, selected from one of the following groups or tautomers thereof 15. A compound according to any of claims 1 to 14, wherein R2 is halogen or C1-7 alkoxy and m is selected from 0, 1, 2 or 3. 16. A compound according to claim 15, wherein R2 is fluoro or methoxy and m is selected from 1 or 2. 17. A compound according to claim 1 selected from the group consisting of: and pharmaceutically acceptable salts thereof. 18. A pharmaceutical composition comprising a compound according to any of claims 1-17 together with a pharmaceutically acceptable carrier. 19. A method for the treatment or prevention of diseases or disorders where bromodomain inhibition is desired comprising administering to a subject in need.,., thereof a therapeutically effective amount of a compound according to any of claims 1-17. 20. A method according to claim 19, wherein the disease or disorder is an autoimmune disease, an inflammatory disease or cancer. 21. Use of a compound according to any of claims 1-17 in the manufacture of a medicament for the treatment or prevention of diseases or disorders where bfomodomain inhibition is desired. 22. Use according to claim 21, where the disease or disorder is an autoimmune disease, inflammatory disease or cancer.